Monitoring treatment response in Crohn's disease by af Björkesten, Clas-Göran
Institute of Clinical Medicine 
University of Helsinki 
Helsinki, Finland 
 
and 
 
Division of Gastroenterology 
Department of Medicine 
Helsinki University Central Hospital 
Helsinki, Finland 
 
 
 
 
 
 
Monitoring treatment response in 
Crohn’s disease 
 
 
 
 
 
Clas-Göran af Björkesten 
 
 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
 
To be presented, 
with permission of the Medical Faculty of the University of Helsinki,  
for public examination in Lecture Hall 3 of Biomedicum Helsinki, 
on Friday, February 28th 2014, at 12 noon 
 
Helsinki 2014 
  
 
Supervised by Professor Martti Färkkilä 
   Institute of Clinical Medicine, University of Helsinki 
   and 
   Division of Gastroenterology, Department of Medicine 
   Helsinki University Central Hospital 
   Helsinki, Finland 
 
 
Reviewed by Professor Katri Kaukinen 
   School of Medicine, University of Tampere 
   Seinäjoki Central Hospital 
   and 
   Department of Gastroenterology and Alimentary Tract Surgery 
   Tampere University Hospital 
   Tampere, Finland 
 
   Docent Pekka Collin 
   School of Medicine, University of Tampere 
   and 
   Department of Gastroenterology and Alimentary Tract Surgery 
   Tampere University Hospital 
   Tampere, Finland 
 
 
Opponent  Professor Simon Travis 
   Translational Gastroenterology Unit 
   John Radcliffe Hospital 
   Oxford, United Kingdom 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISBN 978-952-10-9756-0 (paperback) 
ISBN 978-952-10-9757-7 (PDF) 
 
Unigrafia 
Helsinki 2014 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Marit, Emil, Linn & Hanna 
  
  
 
 
 5 
 
CONTENTS  
LIST OF ORIGINAL PUBLICATIONS .............................................................7 
ABBREVIATIONS ..........................................................................................8 
ABSTRACT .....................................................................................................9 
INTRODUCTION ........................................................................................ 11 
REVIEW OF THE LITERATURE ................................................................... 13 
1 Epidemiology and outcome of Crohn’s disease......................................................... 13 
2 Aetiology and pathogenesis of Crohn’s disease ........................................................ 13 
2.1 Genetics ........................................................................................................................ 14 
2.2 Environmental factors ..................................................................................................... 14 
2.3 Role of microbiota .......................................................................................................... 15 
2.4 Role of immune response................................................................................................ 15 
3 Disease classification by phenotype ......................................................................... 16 
4 Diagnosis ................................................................................................................... 17 
4.1 Clinical presentation ....................................................................................................... 18 
4.2 Laboratory tests ............................................................................................................. 18 
4.3 Endoscopy ..................................................................................................................... 19 
4.4 Imaging techniques ........................................................................................................ 21 
4.5 Histology ....................................................................................................................... 22 
5 Treatment ................................................................................................................. 22 
5.1 Medical therapy .............................................................................................................. 22 
5.1.1 Anti-TNFα antibodies .............................................................................................. 23 
5.2 Surgery .......................................................................................................................... 25 
5.3 Nutritional therapy.......................................................................................................... 25 
6 Assessment of disease activity ................................................................................. 26 
6.1 Clinical activity ............................................................................................................... 27 
6.2 Endoscopic activity and mucosal healing .......................................................................... 30 
6.2.1 Anti-TNF therapy and mucosal healing ..................................................................... 30 
6.3 Endoscopic scoring of inflammatory activity ..................................................................... 31 
6.3.1 CDEIS .................................................................................................................... 31 
6.3.2 SES-CD .................................................................................................................. 33 
6.3.3 Other scores .......................................................................................................... 34 
6.4 Histological activity ......................................................................................................... 35 
6.5 Blood tests ..................................................................................................................... 35 
6.5.1 Cytokines and serological biomarkers....................................................................... 36 
6.5.2 Radio-labelled neutrophils ....................................................................................... 36 
6.6 Intestinal permeability tests ............................................................................................ 36 
6.7 Faecal tests .................................................................................................................... 37 
6.7.1 Calprotectin ........................................................................................................... 38 
6.7.2 S100A12, lactoferrin, and polymorphonuclear neutrophil elastase .............................. 39 
6.8 Combined activity scores ................................................................................................. 40 
6.9 Tools for assessing efficacy of anti-TNF therapy in CD ...................................................... 41 
AIMS OF THE STUDY ................................................................................. 43 
 6 
 
PATIENTS AND METHODS ......................................................................... 44 
1 IBD-HOT study .......................................................................................................... 44 
2  Patients ..................................................................................................................... 44 
2.1 Retrospective studies (I, III) ........................................................................................... 44 
2.1.1 Patients in Study I .................................................................................................. 44 
2.1.2 Patients in Study III ............................................................................................... 44 
2.2 Prospective studies (II, IV) ............................................................................................. 45 
2.2.1 Patients in Study II ................................................................................................. 45 
2.2.2 Patients in Study IV ................................................................................................ 45 
3 Methods .................................................................................................................... 46 
3.1 Endoscopic scoring ......................................................................................................... 46 
3.2 Faecal calprotecin and blood tests ................................................................................... 47 
3.3 Clinical activity scores ..................................................................................................... 47 
3.4 Statistics ........................................................................................................................ 47 
3.5 Ethics ............................................................................................................................ 48 
RESULTS .................................................................................................... 49 
1 Predicting long-term endoscopic response .............................................................. 49 
1.1 Endoscopic assessment as a predictor for long-term treatment response ........................... 49 
1.2 Non-invasive disease-activity assessment as a predictor for long-term treatment response . 54 
2 Non-invasive markers of disease activity as replacement for endoscopy ................ 55 
3 A non-invasive combination score for detecting endoscopic remission ................... 58 
DISCUSSION.............................................................................................. 60 
1 Endoscopy as a predictor of long-term endoscopic outcome ................................... 60 
2 Surrogate markers as replacement for endoscopy and in predicting long-term 
outcome ............................................................................................................................ 62 
3 Identifying endoscopic remission by combining non-invasive markers and clinical 
indices ............................................................................................................................... 65 
CONCLUSION ............................................................................................. 66 
FINNISH AND SWEDISH SUMMARIES ...................................................... 67 
ACKNOWLEDGEMENTS .............................................................................. 69 
REFERENCES.............................................................................................. 72 
 
 7 
 
LIST OF ORIGINAL PUBLICATIONS 
 
 
 
 
This thesis is based on the following original publications: 
 
I af Björkesten CG, Nieminen U, Turunen U, Arkkila PE, Sipponen T, Färkkilä MA. 
Endoscopic monitoring of infliximab therapy in Crohn’s disease. Inflammatory 
Bowel Diseases 2011;17(4):947-53. 
 
 
II af Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M. 
Mucosal healing at 3 months predicts long-term endoscopic remission in anti-
TNF-treated luminal Crohn’s disease. Scandinavian Journal of Gastroenterology 
2013;48(5):543-51. 
 
 
III Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho 
KL, Färkkilä MA, Sipponen T. Fecal calprotectin concentration predicts outcome 
in inflammatory bowel disease after induction therapy with TNFα blocking agents. 
Inflammatory Bowel Diseases 2012;18(11):2011-7. 
 
 
IV af Björkesten CG, Nieminen U, Turunen U, Arkkila PE, Sipponen T, Färkkilä MA. 
Surrogate markers and clinical indices, alone or combined, as indicators for 
endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scandinavian 
Journal of Gastroenterology 2012;47(5):528-37. 
 
 
The original publications are published with permission from the copyright holders* and 
are referred to in the text by their Roman numerals. 
 
*I, III: Wolter Kluwer Health; II, IV: Informa Healthcare 
 8 
 
ABBREVIATIONS 
 
anti-TNF  anti-tumour necrosis factor-α antibodies 
ASCA   anti-Saccharomyces cerevisiae antibodies 
ATG16L1  autophagy-related protein 16-1 gene 
CARD   caspase-activating recruitment domain 
CBir1   anti-flagellin antibody 
CD    Crohn’s disease 
CDAI   Crohn’s disease activity index 
CDEAS  Crohn’s disease endomicrosopic activity score 
CDEIS   Crohn’s disease endoscopic index of severity 
CLE   confocal laser endomicroscopy 
51Cr-EDTA  chromium-ethylene diamine tetra-acetic acid  
CRP    C-reactive protein 
CT    computed tomography 
DBE   double-balloon enteroscopy 
ELISA   enzyme-linked immunosorbent assay 
ESR    erythrocyte sedimentation rate 
GI   gastrointestinal 
HBI    Harvey-Bradshaw index 
Hct   haematocrit 
hsCRP  high sensitivity C-reactive protein 
kDa    kilodalton 
IBD    inflammatory bowel disease 
IBD-HOT  Inflammatory bowel disease – Health Outcome of Treatment study 
IBD-U  inflammatory bowel disease – unclassified 
IBS    irritable bowel syndrome 
IFN    interferon 
IL    interleukin 
MAP   Mycobacterium avium paratuberculosis 
MRI    magnetic resonance imaging 
NBI   narrow-band imaging 
NOD   nucleotide oligomerisation domain 
ompC   outer-membrane porin C 
pANCA   anti-neutrophil cytoplasmic antibody with perinuclear staining pattern 
PCDAI   paediatric Crohn’s disease activity index 
PDAI   perianal Crohn’s disease activity index 
PEG    polyethylene glycol 
PMN-e  polymorphonuclear neutrophil elastase 
ROC curve  receiver operator characteristic curve 
SBCE   small bowel capsule endoscopy 
SBE    small bowel enteroclysis 
SBFT   small bowel follow-through 
SES-CD   simple endoscopic score for Crohn’s disease 
99Tc-DPTA  diethylene triaminepentaasectic acid 
Th   T-helper 
TNFα  tumour necrosis factor-α 
UC   ulcerative colitis 
US   ultrasound  
 9 
 
ABSTRACT 
Background 
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) most commonly 
affecting the colon and terminal ileum. It has typically a relapsing and remitting course, 
with its worsening characterised by diarrhoea, abdominal pain, and bloody stools. One 
of the fundamental goals in the treatment of CD should be mucosal healing, because 
complete disappearance of mucosal ulcerations has been associated with a significantly 
better outcome: improvement of quality of life and reduction of hospitalization and need 
for surgery. Endoscopic indices such as the simple endoscopic score for Crohn’s disease 
(SES-CD) have been developed and validated for assessment of luminal inflammatory 
activity. Traditional assessment of CD activity, however, has been based on symptoms 
and clinical signs, although symptoms sometimes fail to correlate with bowel 
inflammatory activity. The role of clinical indices such as the Crohn’s disease activity 
index (CDAI) and the Harvey-Bradshaw index (HBI), and surrogate laboratory markers 
such as faecal calprotectin to indicate CD remission determined by endoscopy is 
unsettled. Furthermore, studies on predictive markers for endoscopic outcome in CD 
treated with anti-tumour necrosis factor-α antibodies (anti-TNF) are limited.  
Patients and methods 
Data on 71 patients with active luminal CD who were treated with infliximab underwent 
retrospective analysis to assess any features predicting long-term outcome (Study I). All 
patients underwent endoscopy at baseline and at three months from start of infliximab, 
whereas further twelve-month endoscopic follow-up data were available for 57 patients. 
CD activity was scored by reassessment of the existing endoscopy reports.  
Study II included prospectively collected data from 42 patients with endoscopically 
active luminal CD treated with anti-TNF, followed up for one year from start of anti-
TNF. All patients received anti-TNF for at least three months, after which they 
underwent endoscopic assessment. Endoscopic or clinical response legitimised anti-TNF 
continuation. All patients had data on either the SES-CD obtained approximately one 
year from start of anti-TNF, or data on bowel surgery during follow-up. Laboratory data 
were analysed, and clinical activity was assessed with the CDAI at baseline and in 
connection with the follow-up endoscopies. 
To assess the predictive role of faecal calprotectin measured after anti-TNF induction, a 
retrospective study began that comprised 60 IBD patients, including 34 patients with 
luminal CD (Study III). These patients were divided into groups according to 
calprotectin levels measured after anti-TNF induction, and anti-TNF was continued in 
all those with an endoscopic or clinical response. Clinical CD activity was assessed by the 
HBI one year from start of anti-TNF.  
Study IV included 64 CD patients with prospective follow-up data on 210 endoscopies 
and at least one concurrent non-invasive disease activity marker. Mucosal inflammatory 
activity was scored according to the SES-CD and compared with available concurrent 
 10 
 
clinical indices and laboratory markers, and different scores were based on their 
combinations.  
Results 
Among patients continuing anti-TNF as maintenance therapy, twelve-month endoscopic 
remission was significantly more common in those patients who had been in endoscopic 
remission at three months, than in those with endoscopically active disease at three 
months (90% vs. 33% in Study I, p=0.0001; 70% vs. 17% in Study II, p=0.003), and the 
three-month SES-CD predicted twelve-month endoscopic remission with 88% 
sensitivity and 64% specificity (Study II). No patient with endoscopically inactive disease 
at three months underwent surgery during the follow-up. The calprotectin cut-off, 139 
μg/g, had a sensitivity of 72% and specificity of 80% to predict one-year clinical relapse. 
A calprotectin decline of more than 88% during anti-TNF induction predicted clinical 
remission at one year with a sensitivity of 87% and specificity of 65% (Study III). 
Neither C-reactive protein (CRP) nor the CDAI at three months was capable of showing 
any connection with twelve-month endoscopic remission (Study II). 
The SES-CD demonstrated a stronger correlation with calprotectin (r=0.56, p<0.001) 
and CRP (r=0.56, p<0.001) than with the CDAI (r=0.40, p<0.001) or HBI (r=0.32, 
p<0.001) (Study IV). With the use of widely accepted cut-offs, the CDAI and the HBI 
indicated clinical remission almost three times as often, and CRP was normal nearly 
twice as often as when the SES-CD indicated remission. CRP and clinical index cut-off 
optimisation improved only slightly their power to detect endoscopic remission. 
However, although faecal calprotectin alone identified endoscopic remission with 84% 
sensitivity and 74% specificity, it was beaten, but not statistically significantly, by a 
combined index based on calprotectin and the HBI (sensitivity 86%, specificity 82%) 
(Study IV). Although the clinical indices and CRP, used alone or in combination, proved 
inferior to calprotectin alone, a score based on CRP and the HBI seemed to perform 
better in identifying endoscopic remission than did either test separately. 
Conclusions 
In anti-TNF-treated active luminal CD, endoscopic remission at three months is a useful 
predictor for maintenance of a long-term endoscopic response. CRP and clinical indices 
commonly used in the assessment of disease activity and treatment response are, both 
alone and combined, inferior to faecal calprotectin at determining mucosal inflammatory 
activity and detecting endoscopic remission. In patients on scheduled anti-TNF therapy, 
a normal faecal calprotectin after anti-TNF induction is a predictor of sustained clinical 
remission. Evidently it also may be able to predict long-term endoscopic remission. 
Moreover, a score based on a combination of calprotectin and the HBI may function as 
a new tool for identifying endoscopic remission. For optimisation of anti-TNF therapy 
in active luminal CD in clinical practice, these study results suggest an objective 
inflammatory activity assessment such as ileocolonoscopy or determination of faecal 
calprotectin, performed as early as three months after initiation of therapy.  
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INTRODUCTION 
Crohn’s disease (CD) is a disabling transmural and segmental chronic inflammatory 
bowel disease (IBD) with a relapsing and remitting course. Its inflammatory lesions can 
affect the entire gastrointestinal (GI) tract, in contrast to the other major type of IBD, 
ulcerative colitis (UC), which is limited solely to the colon (Baumgart and Sandborn 
2007). The aetiology and pathogenesis of CD is incompletely known, but the most 
widely accepted hypothesis is that it arises from interactions between immunoregulatory, 
genetic, and environmental factors (Baumgart and Carding 2007). Exacerbations in CD 
are characterised by symptoms such as diarrhoea, abdominal pain, and rectal bleeding. 
Assessment of CD activity has traditionally been based on symptoms and clinical signs, 
although symptoms sometimes fail to correlate with bowel inflammatory activity. 
Despite great advances in development of medical therapy during the last two decades, 
CD is still considered incurable, and in many patients leads to multiple complications 
(Loftus 2006). Although surgery as a treatment option is limited to complications such as 
strictures and fistulae, despite optimized medical therapy, surgery will ultimately be 
necessary in up to 70% of cases (Bernell et al. 2000).  
 
During the era of therapy with anti-tumour necrosis factor-α antibodies (anti-TNF), 
complete disappearance of mucosal ulcerations has been associated with favourable 
outcome, and after initiation with anti-TNF, complete mucosal healing has been the only 
factor predicting long-term steroid-free remission (Hommes and van Deventer 2004, 
Rutgeerts et al. 2007). Accordingly, for assessing CD activity, for tailoring therapy, and 
for measuring treatment response, objective determination of inflammatory activity 
should be essential. In anti-TNF-treated CD, the cost-effect dimension and the fact that 
a significant proportion of patients may fail to respond to therapy make identifying 
predictors of response to anti-TNF also important. These predictors, by allowing a 
better selection of patients, would thereby reduce the associated health care costs. The 
gold standard for assessment of luminal inflammation in CD is endoscopy with biopsies, 
but the role of endoscopy as a disease-activity monitoring and prognostic tool in anti-
TNF-treated CD is insufficiently established.  
 
Additionally, because endoscopic procedures are time-consuming, expensive, and 
unpleasant for patients, surrogate markers of mucosal inflammation are currently under 
intensive investigation. To reveal intestinal inflammation, conventional laboratory 
markers in the blood such as haemoglobin, C-reactive protein (CRP), or erythrocyte 
sedimentation rate (ESR) have proved insufficiently sensitive (Cellier et al. 1994, Desai et 
al. 2007). Faecal calprotectin, an inflammatory product of the intestinal mucosa, has 
repeatedly been correlated in luminal CD with both endoscopic and histological findings; 
low calprotectin concentration has also served as a surrogate marker for endoscopically 
and histologically inactive disease (Roseth et al. 1999, Sipponen et al. 2008a). The role of 
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surrogate markers of inflammatory activity is, however, still an open question; for 
example their cut-off values for remission in anti-TNF-treated luminally active CD are 
unclear (Lewis 2011). The existing non-invasive scores developed for disease activity 
assessment are infrequently used in clinical practice. These scores are mainly based on 
clinical symptoms and show only weak correlations with endoscopically determined 
inflammatory activity (Cellier et al. 1994, Sipponen et al. 2008c). Few have attempted to 
develop combined scores consisting of clinical findings and symptoms and laboratory 
markers to improve the identification of luminal inflammatory activity (Langhorst et al. 
2008).  
 
This thesis aims to evaluate the role of endoscopy in monitoring maintenance anti-TNF 
therapy and predicting long-term response to anti-TNF, to analyze the role of surrogate 
markers and clinical indices in comparison to endoscopic disease activity in active 
luminal CD, and further to develop methods for predicting long-term efficacy of anti-
TNF treatment. Additionally, it aims to assess the accuracy of surrogate and clinical 
indices, alone or in combination, in identifying endoscopically determined remission.  
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REVIEW OF THE LITERATURE 
Crohn’s disease, also known as regional enteritis, terminal ileitis, granulomatous ileitis, 
hyperplastic ileitis, and chronic ulcerative ileitis, is named after the American 
gastroenterologist Burrill B. Crohn, who, together with his colleagues Leon Ginzburg 
and Gordon D. Oppenheimer, described 14 patient cases with regional enteritis over 80 
years ago (Crohn et al. 1932). A transmural inflammatory disease of the GI mucosa 
capable of affecting any part of the GI tract, CD is characterized by a chronic course 
with phases of remission interrupted by unpredictable worsening episodes or relapses. 
Some patients may have chronically active disease, meaning continuously active 
inflammation (Baumgart and Sandborn 2007). 
 
 
1 Epidemiology and outcome of Crohn’s disease 
CD shows a small female preponderance, gender ratios depending, however, on age and 
geographic region (Brant and Nguyen 2008). Typically, CD manifests in adolescents, but 
approximately 20% develop symptoms in childhood (Heyman et al. 2005, Nikolaus and 
Schreiber 2007). The highest incidence and prevalence rates occur in developed 
countries with annual incidences of up to 16.3/100,000 and prevalences of 213/100,000 
(Loftus 2004, Lapidus 2006, Baumgart and Carding 2007, Bernstein and Shanahan 2008). 
Annually, Europe has an estimated 23,000 to 41,000 new CD cases, with the incidence 
still rising (Loftus 2004). Distinct north-south and west-east gradients exist within 
Europe, with the highest rates in northern and western countries, but the incidences in 
southern and eastern Europe are increasing faster (Shivananda et al. 1996, Burisch et al. 
2013). The IBD incidence in Finland is globally among the highest, with recent studies 
reporting locally increasing but nationally more stable CD incidences during the previous 
decade (Manninen et al. 2010, Jussila et al. 2012). Age below 40 years, perianal 
involvement, and need for corticosteroid therapy at the time of diagnosis are factors 
predicting a more disabling course (Beaugerie et al. 2006). The life expectancy of patients 
with CD is slightly lower than average (Persson et al. 1996, Wolters et al. 2006, Manninen 
et al. 2012). Despite improved medical knowledge and available therapy, no significant 
decrease has occurred in mortality for CD patients over the last several decades (Loftus 
2006). 
 
 
2 Aetiology and pathogenesis of Crohn’s disease 
Despite marked improvement in the understanding of immunological mechanisms 
during recent years, the exact aetiological factors involved in the pathogenesis of CD 
remain elusive. The prevailing hypothesis is that a disturbed interaction of the host 
 14 
 
immune system with its commensal microbiota and other luminal agents leads to 
damaged bowel mucosa (Baumgart and Carding 2007). 
 
2.1 Genetics 
The strongest risk factor for CD is having a relative with that same disease. First-degree 
relatives of patients with CD have a 12- to 15-fold greater risk for developing the disease 
than do people of comparable age in the general population (Simmons et al. 2000). 
Patients with CD have a first-degree relative with IBD in up to 22% of cases (Gaya et al. 
2006). The inherited predisposition is also demonstrated by the higher prevalence of CD 
among Jewish people than among any other ethnic group, and by a pooled concordance 
of 36% in monozygotic twins (Rosenstiel et al. 2009). Several genes have been related to 
CD. Those genes are related to innate pattern-recognition receptors, to epithelial barrier 
homeostasis and maintenance of epithelial barrier integrity, to autophagy, and to 
lymphocyte differentiation. Thus far, the strongest and most often replicated 
associations with CD have been done with CARD15/NOD2, IL23R, and ATG16L1 
genes. The gene encoding caspase-activating recruitment domain 15 (CARD15) – also 
known as the nucleotide oligomerisation domain 2 (NOD2) – plays a key role in innate 
host defence, and its mutations associate strongly with CD affecting the ileum and 
particularly with stricturing disease (Gaya et al. 2006). CARD15 seems to be not only a 
susceptibility gene, but also a disease-modifier gene for CD. Furthermore, studies have 
revealed that CD susceptibility is associated with several polymorphisms of the IL-23 
receptor (IL-23R) gene locus and single nucleotide polymorphisms in the regions of the 
autophagy gene ATG16L1 (Duerr et al. 2006, Cadwell et al. 2008). Recently, a genome-
wide association meta-analysis defined more than 70 distinct CD susceptibility loci 
(Franke et al. 2010).  
 
2.2 Environmental factors 
Diet, microbiota, use of nonsteroidal anti-inflammatory drugs, and high hygiene level 
have all attracted study interest as triggers for CD. For example, diets high in sucrose, 
refined carbohydrates, and omega (ω)-6 polyunsaturated fatty acids, and diets low in 
fruits and vegetables seem associated with increased risk for CD (Neuman and Nanau 
2012). Nevertheless, the associations between cigarette smoking and CD are by far the 
best studied: current smoking elevates the risk for developing the disease, it adversely 
affects the course of the disease, raises exacerbation rates, promotes complications and 
risk for surgery; and smoking cessation may lead to lessening of disease severity (Cosnes 
et al. 2001, Mahid et al. 2006, Higuchi et al. 2012). 
 
 15 
 
2.3 Role of microbiota 
Metagenomic research suggests that up to four major bacterial phyla (Bacteroidetes, 
Firmicutes, Actinobacteria, and Proteobacteria), consisting of thousands of mostly 
anaerobic species, colonise the human gut. Variation in bacterial-species diversity in the 
gut depends upon temporal, individual, dietary, and drug-induced factors (Costello et al. 
2009, Turnbaugh et al. 2010, Muegge et al. 2011, Dethlefsen and Relman 2011). 
However, healthy intestinal microbiota variation is generally stratified and not continous 
(Arumugam et al. 2011). In patients with CD, studies have showed clustering and 
reduced diversity, especially within the Firmicutes and Bacteroides phyla; reduction in 
the Firmicute Faecalibacterium prausnitzii has been associated with increased risk for 
postoperative recurrence of ileal CD (Frank et al. 2007, Sokol et al. 2008, Qin et al. 2010, 
Willing et al. 2010). Higher levels of Mycobacterium avium paratuberculosis (MAP) may occur 
in the tissues and blood of CD patients than in controls, but despite considerable 
research, the role of MAP in CD pathogenesis remains inconclusive (Chiodini et al. 1984, 
Bull et al. 2003). MAP in CD currently attracts, however, mostly academic interest 
because there exists no clinically useful test to identify its presence nor any evidence to 
support the use of antimicrobials to eradicate it (Bernstein et al. 2004, Selby et al. 2007). 
 
2.4 Role of immune response 
In CD, the chronic autoimmune intestinal inflammatory process results from 
pathological interaction of the immune system with commensal enteric bacteria (Xavier 
and Podolsky 2007). The mucosal host defence deteriorates due to abnormalities in the 
innate immune response and adaptive immune system. The innate immune system 
provides the nonspecific defence against pathogens by means of macrophages, dendritic 
cells, natural killer cells, neutrophils, and the complement system. Responses of these 
components are inborn and not tailored to any particular immunological challenge. As a 
consequence of mucus biofilm insufficiency and decreased excretion of antimicrobial 
agents in epithelial cells, the normally tight seals between cells become leaky, resulting in 
increased permeability and an access of luminal antigens into the lamina propria (Buisine 
et al. 1999, Söderholm et al. 2002). Dendritic cells express a wide range of pattern-
recognition receptors and interpret microbial patterns to direct other immune cells 
towards immunity or tolerance (Niess et al. 2005). When dendritic cells lose their ability 
to induce regulatory T cells, this leads to loss of tolerance of microbial antigens or to the 
induction of cross-reactive autoimmune responses (Sartor 2008, Iliev et al. 2009).  
The adaptive immune system is slower than the innate immune system, and the 
secondary response is more specifically tailored through function of T- and B-
lymphocytes. In CD, this system is thought to mediate and maintain, but probably not 
initiate, intestinal inflammation (Baumgart and Carding 2007). The patchy transmural 
inflammation characteristic of CD is associated with activation of types 1 and 17 T-
helper (Th) cells in response to production of interleukins (IL) and transforming growth 
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factor β by antigen-presenting cells and macrophages. Th1 and Th17 cells, in turn, cause 
increased secretion of the pro-inflammatory cytokines IL-2, IL-17, interferon (IFN)-γ, 
and tumour necrosis factor-α (TNFα). These cytokines feed into a self-sufficient cycle 
whereby they stimulate antigen-presenting cells, macrophages, fibroblasts, and 
endothelial cells to produce TNFα, IL-1, IL-6, IL-8, IL-12, and IL-18 (Collison et al. 
2010, Engel and Neurath 2010, Franke et al. 2010). 
 
3 Disease classification by phenotype 
Typical presentations of CD include discontinuous involvement of various portions of 
the GI tract and development of disease complications such as strictures, fistulae, or 
abscesses. At diagnosis, about half the patients present with purely terminal ileitis, in 
approximately one-quarter both the terminal ileum and colon are affected, and in about 
one-quarter only the colon is involved (Baumgart and Sandborn 2007). In less than one-
tenth of all patients, CD may affect the ileum out of reach of ileocolonoscopy or involve 
the more proximal small bowel or the upper GI tract. Additionally, at the time of 
diagnosis, 15% of patients have penetrating lesions, meaning fistulae or abscesses (Van 
Assche et al. 2010a). Disease classification allows clinicians to differentiate among the 
features and behaviours of CD. The 2005 Montreal revision of the Vienna classification 
is regarded as the international standard of CD phenotype subtyping (Gasche et al. 2000, 
Satsangi et al. 2006) (Table 1). 
 
 
Table 1. Vienna and Montreal classifications for Crohn’s disease  
 
Age at diagnosis A1  <40 years A1  ≤16 years 
 A2  ≥40 years A2  17–40 years 
  A3  >40 years 
Localisation L1  ileal L1  ileal 
 L2  colonic L2  colonic 
 L3  ileocolonic L3  ileocolonic 
 L4  upper L4  isolated upper disease* 
Behaviour B1  non-stricturing, non-penetrating   B1  non-stricturing, non-penetrating 
 B2  stricturing B2  stricturing 
 B3  penetrating B3  penetrating 
  p  perianal disease modifier** 
* L4 is a modifier that can be added to L1-L3 when concomitant upper gastrointestinal disease is present, 
** The modifier ―p‖ is added to B1–B3 when concomitant perianal disease is present. 
Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease: controversies, 
consensus, and implications. Gut 2006;55:749-753. Reproduced with permission from BMJ Publishing Group Ltd. 
 
A well-established fact is that after diagnosis of adult patients, location subtyping 
remains stable, whereas behaviour subtyping changes continuously, with an increasing 
proportion of patients progressing from inflammatory disease to stricturing or 
 17 
 
penetrating disease (Louis et al. 2001, Cosnes et al. 2002). According to one follow-up 
study of new CD cases, however, changes in disease location were apparent at 5 years in 
13.5% and in disease behaviour in 17.5% of patients. In ileal CD patients, stricturing 
complications were evident in 64%, but in only 6% of patients with colonic CD 
(Henriksen et al. 2007). 
 
4 Diagnosis 
As there exists no single method to diagnose CD, Lennard-Jones and Shivananda (1997) 
with the European IBD study group have defined macroscopic and microscopic criteria 
for establishing diagnosis. Macroscopic diagnostic tools include physical, endoscopic, 
and radiological examination, and examination of a surgical specimen. Microscopic 
features can only in part be analysed by mucosal biopsy, but can be completely analysed 
in a surgical specimen. Diagnosis is based on the finding of noncontinuous and often 
granulomatous intestinal inflammation. Current opinion is that diagnosis is, in practice, 
established by a loosely defined combination of clinical presentation, endoscopic 
features, radiological findings, histological appearance, surgical findings and, more 
recently, serological abnormalities (Van Assche et al. 2010a). In clinical practice, CD and 
UC can typically be differentiated by their clinical characteristics. The main differences 
between CD and UC are location and nature of the inflammatory changes (Table 2). 
 
 
Table 2. Signs and findings differentiating Crohn’s disease and ulcerative colitis in 
adult patients  
 Crohn’s disease Ulcerative colitis 
   
Stool consistency 
Often porridge-like, sometimes 
steatorrhoea 
Often mucus-like 
Tenesmus Less common More common 
Fever Common Indicates severe disease 
Fistulae Common Rare 
Weight loss Often More seldom 
Terminal ileum involvement Common Rare 
Colon involvement Common Always 
Rectum involvement More seldom Nearly always 
Perianal involvement Common Rare 
Distribution of disease Patchy inflammation Continuous area of inflammation 
Ulcers seen in endoscopy Deep geographic, snake-like Continuous, superficial 
Strictures Common Rare 
Depth of inflammation  Transmural Limited to mucosa 
Granulomatous inflammation Common Absent 
Presence of antimicrobial antibodies: 
ASCA, anti-Cbir1, anti-OmpC 
More often Seldom 
   
ASCA:  anti-Saccharomyces cerevisiae antibodies; anti-Cbir1:  anti-flagellin antibody; anti-OmpC:  Escherichia coli 
outer membrane porin C antibody.     
Data from from Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and 
during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 
1997;9:353-359 and Van Assche G, Dignass A, Panes J et al. The second European evidence-based consensus on the 
diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohns Colitis 2010;4:7-27. 
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The term ―inflammatory bowel disease – unclassified‖ (IBD-U) is appropriate in 
situations where a definitive distinction between CD, UC, or other causes of colitis is 
impossible despite appropriate diagnostic assessment (Satsangi et al. 2006). Indeterminate 
colitis is a pathological-anatomical diagnosis reserved for pathologists to describe a 
colectomy specimen with overlapping features of CD and UC (Price 1978, Satsangi et al. 
2006). 
 
4.1 Clinical presentation 
Symptoms in CD are heterogeneous and depend on disease location and behaviour. 
Chronic diarrhoea is the most common symptom, affecting up to 85% of patients 
(Sands 2004). Abdominal pain occurs in approximately 70% and weight loss in 60% of 
patients before diagnosis, and in CD patients with colonic disease, bloody or mucous 
stools or both occur in up to 50% (Lennard-Jones and Shivananda 1997). Fever, rectal 
pain, and fatigue may also be present. More acute presentations may occur, and acute 
terminal ileal CD may even be mistaken for acute appendicitis. CD can also cause 
unexplained anaemia, chronic non-specific symptoms resembling irritable bowel 
syndrome (IBS), and, in children, growth failure (Burgmann et al. 2006). On the other 
hand, as IBS is up to three times as prevalent in IBD as in the non-IBD population, 
symptoms compatible with IBS can sometimes dominate the clinical picture despite IBD 
remission (Simrén et al. 2002). Up to 30% of patients also present with extraintestinal 
manifestations such as peripheral arthropathy, axial arthritis, ocular (uveitis, episcleritis), 
cutaneous (erythema nodosum, pyoderma gangraenosum), or hepatobiliary disease 
(primary sclerosing cholangitis). Extraintestinal manifestations are most common when 
CD affects the colon. At diagnosis, 10% of patients have perianal fistulae (Schwartz et al. 
2002, Van Assche et al. 2010a). 
In physical examination, a CD patient may be underweight and even malnourished. Ileal 
CD can present with pain in the right lower abdomen. Palpation may indicate an 
abdominal mass or may cause pain. Discovery of perianal fistulae or fissures may follow 
anal inspection or rectal palpation. Small aphthous ulcers may be evident in the oral 
cavity (Van Assche et al. 2010a). 
 
4.2 Laboratory tests 
In the full blood count of CD patients, anaemia and thrombocytosis are the most 
common changes. ESR and CRP may be elevated, and albumin levels low. Stool tests for 
investigation of pathogenic bacteria, especially Clostridium difficile, and parasites are 
necessary to differentiate between IBD and infectious colitis. Stool tests can additionally 
reveal elevated levels of faecal inflammatory markers (Vermeire et al. 2004). Anti-
Saccharomyces cerevisiae antibodies (ASCA) directed against Candida albicans, and perinuclear 
anti-neutrophil cytoplasmic antibodies (pANCA) may, particularly in difficult cases, be 
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useful in improving diagnostic precision and differentiation between UC and CD 
(Standaert-Vitse et al. 2006). In a meta-analysis of studies involving detection of CD in 
4,019 patients, positive detection of ASCA in combination with lack of pANCA resulted 
in 55% sensitivity and 93% specificity (Reese et al. 2006). Population studies have 
revealed a particular strength of ASCA in its predicting a complicated, severe course of 
the disease (Riis et al. 2007). Positive detection of ASCA is, however, a nonspecific 
finding occurring in up to 60% of patients with coeliac disease, suggesting an immune 
response to commensal microbes inducing mucosal damage (Ashorn et al. 2008). Other 
serum antimicrobial antibodies of IBD patients include the CD-related protein from 
Pseudomonas fluorescens (anti-I2), a flagellin-like antigen (anti-Cbir1), and Escherichia coli 
outer membrane porin C (anti-OmpC) I2 antibodies (Mow et al. 2004, Targan et al. 
2005). These antibodies are detectable in about 50% of CD patients but in only 10% 
with UC. Anti-CBir1 expression is associated independently with small bowel, with 
penetrating, and with stricturing disease (Vernier et al. 2004).  
Patients concurrently positive for ASCA, for anti-ompC, and for anti-I2 are eight times 
as likely as are seronegative patients to require small bowel surgery (Mow et al. 2004). 
These antibody responses may play a role in subtyping CD patients, in prediction of 
disease course, or in differentiation of IBD-U. Serological testing currently available may 
serve as a complement to diagnosis in clinical practice, but because of their inaccuracy, 
even the best available tests are of little use in routine clinical diagnosis (Reese et al. 
2006). Despite huge advances in the field of CD genetics, currently no laboratory genetic 
test exists that can be recommended routinely for diagnosis (Van Assche et al. 2010a).  
 
4.3 Endoscopy 
The gold standard as a first-line diagnostic procedure for suspected CD is full 
ileocolonoscopy providing multiple biopsy specimens. With practice, the ileum can be 
reached in at least 85% of colonoscopies, which enhances diagnosis of CD in patients 
presenting with symptoms of IBD (Coremans et al. 1984). The central endoscopic 
features of CD are discontinuous involvement, anal lesions, and cobblestoning. 
Anatomical criteria of severe disease are deep ulcerations eroding the muscle layer, or 
mucosal detachments or ulcerations limited to the submucosa but extending to more 
than one-third of a specific colonic segment (right, transverse, or left colon) (Nahon et al. 
2002). 
In severe, active disease, however, full ileocolonoscopy leads to increased risk for bowel 
perforation, and diagnostic errors are more frequent. In such circumstances, initial 
flexible sigmoidoscopy is safer, and full ileocolonoscopy should be delayed until the 
patient’s condition improves (Van Assche et al. 2010a). A further diagnostic limitation of 
endoscopy is its inability to detect disease activity beyond the mucosa. 
Irrespective of the findings in ileocolonoscopy, further investigation is recommended to 
determine the location and extent of the disease in the small bowel and upper GI tract 
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(Van Assche et al. 2010a). CD affecting the upper GI tract is almost always accompanied 
by small- or large-bowel involvement. Gastric biopsies may prove useful in a patient with 
IBD-U, as CD may include focal active gastritis in the absence of ulceration (Witte et al. 
1998). Because prevalence rates for CD in the upper GI tract can be high (17–75%), 
especially in symptomatic patients (dysphagia, chest pain, heartburn, dyspepsia, epigastric 
pain), some experts have suggested that all newly diagnosed patients with CD should 
have at least one upper endoscopy (Hommes and van Deventer 2004).  
 
Recently, wireless small-bowel capsule endoscopy (SBCE), device-assisted enteroscopy, 
and new imaging modalities have offered novel possibilities for detecting inflammatory 
lesions in the small bowel where traditional endoscopic and radiologic approaches have 
limitations.  
SBCE, a technique using a wireless miniature encapsulated video camera designed to 
examine the entire small bowel and directly visualize small bowel lesions, is useful in 
suspicion of small bowel CD and in assessment of its extent and severity (Fireman et al. 
2003). In patients with IBD-U, SBCE may help distinguish between UC and CD. SBCE 
is superior to small bowel follow-through (SBFT), barium enteroclysis (SBE), and 
conventional computed tomography (CT) in establishing the diagnosis and estimating 
disease extent and is widely considered a first-line examination after negative 
ileocolonoscopy and upper endoscopy (Sandrasegaran et al. 2008, Tillack et al. 2008, 
Riccioni et al. 2012b). SBCE is, however, limited by cost and its inability to provide either 
tissue samples or therapy. Furthermore, because SBCE produces picture data at constant 
speed irrespective of the capsule’s pace through the small bowel, localization of lesions is 
tricky. Absolute contraindications for SBCE are suspected or documented intestinal 
obstruction or strictures. In suspected or verified CD, potential risk for capsule retention 
should therefore always be considered (Hommes and van Deventer 2004). 
 
Double–balloon enteroscopy (DBE) is a device–assisted enteroscopy technique for 
reaching lesions throughout the entire small bowel (Yamamoto et al. 2001). The scope 
may be inserted either orally or anally. As the availability of DBE is limited, it should be 
reserved for situations in which biopsy samples are vital for diagnosis or in which 
dilatation of strictures is required. DBE plays an additional role in retrieval of retained 
capsules, which may avoid surgery. Newer modalities of device–assisted enteroscopy are 
single-balloon enteroscopy and spiral enteroscopy (Riccioni et al. 2012a). 
 
Chromoendoscopy uses various techniques during endoscopy to enhance mucosal detail 
and submucosal vascular pattern. It can be divided into dye-based and dye-less imaging. 
Although dye-based chromoendoscopy yields additional diagnostic value with a three- to 
four-fold higher detection rate of intraepithelial neoplasia, it is time-consuming and 
costly (Kiesslich et al. 2003, Neumann et al. 2011). Dye-less chromoendoscopy, also 
called virtual chromoendoscopy, has therefore been developed. Virtual 
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chromoendoscopy such as narrow-band imaging (NBI) and Fujinon intelligent colour 
enhancement uses light of blue and green wavelengths to enhance detail of the mucosal 
surface and its capillary patterns (Neumann et al. 2009). Confocal laser endomicroscopy 
(CLE) is a recently introduced endoscopic tool making it possible to carry out 
microscopic examination with 1000-fold magnification of the mucosal layer while 
endoscopy is ongoing. Different types of tissue are recognisable, and diseases can be 
diagnosed immediately, facilitating early identification of intraepithelial neoplasia. 
Analysis of in vivo microarchitecture may be helpful in targeting biopsies to relevant areas 
(Neumann et al. 2011). In current diagnostic work-up, however, the role of 
chromoendoscopy and of CLE is insignificant. 
 
4.4 Imaging techniques 
For assessing the small intestine, the current imaging standards are computed 
tomography (CT) and magnetic resonance (MR). Both techniques can determine disease 
extension and activity based on wall thickness and increased intravenous contrast 
enhancement. The extent of these findings, along with the presence of oedema and 
ulcerations, enables categorization of disease severity (Wold et al. 2003). Both CT and 
MR are also the most precise techniques to detect extraluminal complications such as 
fistulae and abscesses. Fluoroscopic examinations are clearly inferior to CT or MR in 
detection of small bowel and extraluminal lesions (Gourtsoyiannis et al. 2006). 
Diagnostic accuracy of CT and of MR in detection of small intestine inflammatory 
lesions are similar, but for diagnosis of CD specifically in the terminal ileum, both are 
inferior to ileoscopy (Horsthuis et al. 2008). CT has greater availability and is less time-
consuming than MR. Imaging examinations need to be repeated, and the IBD 
population is young, so radiation exposure from CT examination may entail increased 
health risks. MR should therefore be considered wherever possible. CT and MR 
examinations of the small intestine require oral luminal contrast for adequate 
distension. Administration of luminal contrast by enteroclysis allows better distention 
than does simple oral ingestion. Nasojejunal tube placement leads, however, to radiation 
exposure and produces discomfort (Negaard et al. 2007).  
 
Transabdominal ultrasound (US)—with or without contrast enhancement and the 
Doppler technique—is another non-ionizing imaging technique providing information 
on disease activity, in particular for CD limited to the ileum (Fraquelli et al. 2005). US is a 
valuable, widely available, and inexpensive tool to assess the site and extent of 
inflammation and possible complications, but difficulty of visualization of deep bowel 
segments and high interobserver variability are significant drawbacks.  
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4.5 Histology 
Analysis of a full ileocolonoscopy biopsy series obtained from all segments of the colon 
(right colon, transverse colon, left colon and sigmoid, and rectum) and the ileum 
produces the most reliable diagnosis of CD (Van Assche et al. 2010a). Samples preferably 
come both from areas involved in the disease and from uninvolved areas. Histological 
examination is routine for IBD diagnosis and is helpful in histological distinction 
between UC and CD. In UC, inflammation is limited to the colon and is superficial, 
whereas in CD it is generally transmural, multifocal, and may contain granulomas. Focal 
(discontinuous or segmental) chronic and patchy inflammation, focal crypt irregularity, 
and granulomas unrelated to crypt injury are the most accepted microscopic features 
which allow CD diagnosis. The presence of granulomas is also the central histologic 
criterion among the Lennard-Jones criteria (Lennard-Jones and Shivananda 1997). The 
transmural character of CD inflammation can be identified only when surgical samples 
are available. Other microscopic features detectable in surgical specimens of CD patients 
are aggregated inflammatory pattern, transmural lymphoid hyperplasia, submucosal 
thickening, fissures, sarcoid granulomas, abnormalities of the enteric nervous system, 
and relatively normal epithelial mucin preservation (Van Assche et al. 2010a). 
Distinguishing between CD and intestinal tuberculosis is a diagnostic challenge, as they 
present analogous histological features, in addition to overlapping clinical, radiological, 
and endoscopic features (Kim et al. 2011). As anti-TNF therapy is associated with a 
higher incidence of tuberculosis with extraintestinal and disseminated infection, the 
recommendation is that patients with a suspicion of infection are thoroughly investigated 
before start of that therapy (Gardam et al. 2003).  
 
 
5 Treatment 
Treatment of active CD requires recognition of disease activity, localization (ileal, 
ileocolonic, colonic, or other), and behaviour (inflammatory, stricturing, or fistulating). 
Even in cases with mild disease, leaving patients without treatment is seldom an option. 
As smoking cessation is associated with a 65% reduction in risk for relapse, stopping 
smoking should be encouraged (Cosnes et al. 2001). 
 
5.1 Medical therapy 
Before the era of corticosteroids, IBD was a fatal disease for a great proportion of 
patients; no other medication has had such a great impact on outcome (Truelove and 
Witts 1955, Malchow et al. 1984). Despite the development of more potent drugs against 
CD during recent decades, the disease is still considered incurable and in many patients it 
leads to surgery and disability. Medical therapy for CD can be divided into therapy aimed 
at induction and at maintenance of remission (Table 3). 
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Table 3. Conventional medical therapy in Crohn’s disease. 
 
Medical therapy Notable References 
   
Corticosteroids: 
   predniso(lo)ne 
   methyl prednisolone 
   budesonide 
Good initial clinical response in most patients, but 
50% either fail to respond or become steroid-
dependent at one year. Only one-third achieve 
mucosal healing. No role in maintaining remission. 
Summers et al. 1979  
Modigliani et al. 1990  
Faubion et al. 2001 
Irving et al. 2007  
 
Mesalazine Limited benefit in induction and maintenance of 
remission. Possible benefit in postoperative treatment 
of small intestinal resection 
Hanauer & Stromberg 2004 
Van Assche et al. 2010b 
Sulphasalazine Can induce clinical remission in mildly active colonic 
disease associated with arthropathy. Limited use due 
to frequent intolerance. 
Summers et al. 1979 
Antibiotics 
   ciprofloxacin 
   metronidazole 
Not first-line therapy. May in combination with 
azathioprine prevent postoperative recurrence.  
Appropriate in infectious complications, perineal 
disease, and in bacterial overgrowth. 
Sutherland et al. 1991  
D'Haens et al. 2008  
Dignass et al. 2010  
Thiopurines: 
   azathioprine  
   6-mercaptopurine 
Induces and maintains remission. Lead to mucosal 
healing in both ileal and colonic disease. Should be 
started in corticosteroid-dependent or -refractory 
disease. Unsuitable for rapid induction. 
D'Haens et al.1997  
D'Haens et al.1999a  
Prefontaine et al. 2009  
Prefontaine et al. 2010 
Methotrexate Less studied than azathioprine. Mucosal healing seems 
to occur during intramuscular therapy. 
McDonald et al. 2012 
 
 
5.1.1   Anti-TNFα antibodies 
In patients with CD, the proinflammatory cytokine TNFα plays a role in the 
inflammatory cascade. Anti-TNFs neutralize by several mechanisms this cytokine and 
thus interrupt the inflammatory cascade. As anti-TNFs are created by biological 
processes, they are also called biological drugs or more simply biologicals.  
 
Infliximab is an intravenously administered murine-derived chimeric monoclonal TNFα 
inhibitor antibody of the immunoglobulin G1 subset; it is the most extensively 
investigated biological drug available for the treatment of IBD. Approximately two-
thirds of patients achieve significant clinical improvement, and nearly half maintain 
clinical remission after one year of maintenance therapy (Hanauer et al. 2002). 
Additionally, infliximab induces – as early as four weeks after initiation of therapy – 
mucosal healing based on endoscopic evaluation. This has been shown to reduce risk for 
recurrence, in addition to reducing hospitalization and surgery (D'Haens et al. 1999b, 
Rutgeerts et al. 2004, Schnitzler et al. 2009). Infliximab is also effective as induction and 
maintenance therapy for fistulizing CD (Sands et al. 2004) and may serve as monotherapy 
or be useful  in combination with other immunomodulating agents, usually given as 
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induction doses at weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks 
(Colombel et al. 2010). 
 
Adalimumab is a subcutaneously administered immunoglobulin G1 isotype monoclonal 
human antibody against TNFα. Evidence indicates that adalimumab is effective as a 
weekly or biweekly dosage for both induction and maintenance of remission (Hanauer et 
al. 2006, Sandborn et al. 2007). It also shows efficacy in treatment of fistulizing CD. The 
EXTEND trial demonstrated complete mucosal healing after 52 weeks in 24% of 
patients on adalimumab compared to 0% on placebo (Rutgeerts et al. 2012). Patients 
who have developed antibodies against infliximab may still benefit from adalimumab 
(Feagan et al. 2012). No randomised controlled trials that systemically compare in CD 
the efficacy of adalimumab and infliximab exist, although based on studies with more or 
less similar study designs and populations, their efficacy has been considered 
comparable. A recent retrospective study of 200 matched anti-TNF naïve CD patients 
reported no significant difference in steroid-free response rates or in adverse effects after 
one and two years (Kestens et al. 2013). Because of its retrospective design, that study 
lacked data on clinical or endoscopic activity. 
 
Certolizumab pegol is a pegylated, subcutaneously administered humanized TNFα-
binding Fab fragment (Schreiber et al. 2005). Multiple studies have shown its efficacy as 
similar to that of the other anti-TNF agents, its effects being more pronounced if the 
patient is anti-TNF naïve. In one randomized, double-blind, placebo-controlled trial of 
adults with moderate-to-severe CD, those who responded to induction therapy with 
certolizumab were more likely to maintain their response and sustain remission at 26 
weeks with continuous certolizumab than were those switched to placebo (Schreiber et 
al. 2007). 
 
The need is strong for further biological drugs, because when one antibody loses 
effectiveness, switching to another becomes necessary. Under study are several biological 
therapies targeted at mechanisms other than blockade of TNFα, including modulation of 
other cytokines, blockade of T cells, and blockade of inflammatory cell migration and 
adhesion (Danese 2012).  
Natalizumab, a blocker of α4-integrin, has shown promising results in CD treatment, but 
severe adverse effects such as reactivation of a human polyomavirus leading to 
progressive multifocal leukoencephalopathy limit its use (MacDonald and McDonald 
2007). Vedolizumab is a fully humanized α4 7 integrin antibody that has passed a 
number of phase-III clinical trials. In clinically moderate to severe CD it has been more 
efficient than placebo in inducing and maintaining clinical remission. As vedolizumab 
modulates gut but not brain lymphocyte migration, it is at least theoretically less likely 
than natalizumab to cause progressive multifocal leukoencephalopathy (Sandborn et al. 
2013c). Apilimod is an inhibitor of the transcription of IL-12 and IL-23, whereas 
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ustekinumab and briakinumab both target the p40 subunit common to IL-12 and IL-23. 
As trials investigating these drugs are still in phases I and II, their long-term effects are 
unclear. However, results indicate that ustekinumab might be useful in patients who 
have failed to respond to anti-TNF therapy (Sandborn et al. 2012). Golimumab is a 
TNFα-blocking monoclonal antibody newly approved for treatment of UC. Its 
advantages compared with adalimumab and infliximab are its once-monthly dosing by 
either intravenous or subcutaneous administration (Sandborn et al. 2013a, b). It has not 
yet advanced into CD trials.  
 
5.2 Surgery 
Although surgery in CD should be limited to complications of the disease such as 
strictures and fistulae, ultimately, a large majority, up to 70%, despite optimized medical 
therapy, will need surgery. Furthermore, up to 40% will need secondary surgery because 
of disease recurrence (Bernell et al. 2000). Despite its revolutionizing effect on CD 
treatment, evidence is still limited as to anti-TNF impact on need for surgery. Population 
surveys during the last two decades have shown inconsistent results, with both declining 
trends in and no changes in need for surgery (Lazarev et al. 2010, Nguyen et al. 2011). 
Subgroup analyses of anti-TNF-responding patients seem to suggest a reduction in the 
need for surgery at a median follow-up of up to three years (Feagan et al. 2008). The 
short follow-up and exclusion of patients with imminent surgical need could, however, 
cause bias. CD patients in northern Europe seem more likely to undergo surgery than in 
southern Europe, suggesting a north-south disease-severity gradient (Wolters et al. 2007). 
To preserve bowel function and minimize risk for intestinal failure, a more conservative 
surgical approach has been adopted during recent decades. In cases with medical 
intractability, internal fistulae, abscesses, symptomatic bowel obstruction, severe 
bleeding, toxic dilatation, or acute perforation, however, surgical resection inevitably 
becomes necessary (Greenstein et al. 1988). Patients with perianal or rectovaginal fistulae 
often need a combination of surgery and medical treatment. In the surgical management 
of small bowel CD, strictureplasty plays a central role. Often considered for 
strictureplasty are isolated strictures under 10 cm in length. A majority of patients 
achieve symptomatic relief, with secondary surgery rates of between 34 and 44% during 
a seven-year follow-up (Larson and Pemberton 2004). 
 
5.3 Nutritional therapy 
Unlike the management of CD in paediatric and adolescent patients, no placebo-
controlled trials involve nutritional therapy for active CD in adult patients. In one 
Cochrane systematic review, however, elemental or polymeric diets were less effective 
than corticosteroids in inducing remission (Zachos et al. 2001). Enteral therapy is 
regarded as appropriate only for adjunctive treatment to support nutrition, not for 
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primary therapy in active CD (Dignass et al. 2010). Omega (ω)-3 fatty acids may have 
anti-inflammatory effects by reducing production of leukotriene B4. Due to the 
heterogeneous study data, however, the efficacy of ω-3 fatty acids in maintaining 
remission remains controversial (Turner et al. 2009). Data in ten systematically reviewed 
studies suggest that enteral nutrition as a complement to an ordinary diet may be useful 
for maintaining remission in patients with CD, although the evidence level is low 
(Yamamoto et al. 2010). 
 
 
6 Assessment of disease activity 
In clinical practice, disease activity assessment relies on clinical history and a 
combination of clinical, laboratory, endoscopic, and radiological findings. Need for 
standardisation and quantification of disease severity in clinical trials has led to 
development of several disease activity indices based on findings or symptoms or their 
combinations. Table 4 presents a summary of those assessment methods of clinical 
activity most commonly used in both clinical practice and trials. 
 
 
Table 4. Crohn’s disease activity assessment in clinical practice and clinical trials 
 
Assessment Feature indicating active CD Commonly used indices 
   
Symptoms and 
findings 
Diarrhoea, bloody stools, abdominal pain, fever, 
arthralgia, weight loss 
CDAI, HBI, PDAI 
Blood tests Elevated CRP, elevated ESR, anaemia, elevated 
platelet count, low albumin 
ESR, blood count, and albumin 
included in several indices 
Faecal markers Elevated calprotectin, elevated lactoferrin  
Endoscopy Mucosal ulcerations, inflammation, strictures CDEIS, SES-CD, Rutgeerts score 
Imaging Fistulae, abscesses, thickened bowel wall, 
strictures, abdominal lymphadenopathy 
 
CD: Crohn’s disease; CDAI: Crohn’s disease activity index; HBI: Harvey-Bradshaw index; PDAI: Perianal disease 
activity index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; CDEIS: Crohn’s disease endoscopic 
index of severity; SES-CD: simple endoscopic score for Crohn’s disease. 
Data from Sostegni R, Daperno M, Scaglione N et al. Review article: Crohn’s disease: monitoring disease activity. Aliment 
Pharmacol Ther 2003;17:11-17 and Vilela EG, Torres HO, Martins FP et al. Evaluation of inflammatory activity in 
Crohn’s disease and ulcerative colitis. World J Gastroenterol 2012;18:872–881. 
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6.1 Clinical activity 
In clinical trials, the score most commonly used is the Crohn’s disease activity index 
(CDAI), which comprises one serological and seven clinical variables (Table 5), with 
scores ranging between 0 and approximately 650 (Best et al. 1976). A CDAI <150 has 
defined clinically inactive disease and >450 severe disease. Some investigators have 
arbitrarily further labeled CDAI scores of 150 to 219 as mildly, and 220 to 450 as 
moderately active disease (Sostegni et al. 2003). One definition for clinical response is a 
reduction of ≥100 points in the CDAI, although some clinical trials have defined 
response as a reduction of ≥70 points (Van Assche et al. 2010a). The CDAI score is 
infrequent in everyday clinical work because of its complex and time-consuming 
calculation and the need for a seven-day diary of symptoms. Although it has seemed to 
perform quite well recently in a postoperative setting, it is unsuitable for use as a primary 
outcome measure in patients with a history of extensive surgery (Walters et al. 2011). 
Further, it is unreliable in patients with a mainly fistulating and stricturing disease. An 
additional feature of the CDAI score is the considerable weight given for scores on 
―general well-being‖ and ―intensity of abdominal pain,‖ which are completely subjective 
(Sostegni et al. 2003). Correlation of the CDAI with ileocolonoscopy findings is weak, 
and the CDAI underestimates endoscopically determined inflammatory activity (Cellier et 
al. 1994, Sipponen et al. 2008a, c). For scoring of clinical disease activity of children and 
adolescents, we have a paediatric Crohn’s disease activity index (PCDAI) (Hyams et al. 
1991). 
 
Table 5. Crohn’s disease activity index (CDAI) 
 
Variable Description 
Weighting 
factor 
Number of liquid stools sum of 7-day numbers 2 
Abdominal pain  sum of 7-day scores, subjectively rated 0–3: none=0, mild=1, 
moderate=2, severe=3  
5 
General well-being sum of 7-day scores, subjectively rated 0–4: generally well=0, 
slightly poor=1, poor=2, very poor=3, terrible=4 
7 
Extraintestinal features number of listed features: arthritis/arthralgia, iritus/uveitis, 
erythema nodosum, pyoderma gangraenosum, aphthous 
stomatitis, anal fissure/fistula/abscess, fever >37.8°C 
20 
Antidiarrhoeal medication use in the previous 7 days: no=0, yes=1 30 
Abdominal mass assessed by palpation: no=0, questionable=2, definite=5 10 
Haematocrit (Hct) women: 42–observed Hct; men: 47–observed Hct 6 
Body weight ideal/observed ratio [1–(ideal/observed)×100] (not below –10) 1 
Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative 
Crohn’s Disease Study. Gastroenterology 1976;70:439-444. Adapted from a figure with permission from Elsevier 
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Unlike the CDAI, the Harvey-Bradshaw index (HBI) notes only symptoms and signs 
over the preceding 24 hours (Table 6). It is based on five clinical variables: general well-
being, graded from 0 to 4 points, abdominal pain and palpable abdominal mass, each 
graded from 0 to 3 points, number of liquid stools per day, and 
complications/extraintestinal features, each graded as one point (Harvey and Bradshaw 
1980). It has been suggested that HBI scores ≤4 or <4 indicate clinical remission (Best 
2006, Vermeire et al. 2010).  
 
 
Table 6. Harvey-Bradshaw index (HBI) 
 
Variable Description 
General well-being  very well=0, slightly below par=1, poor=2, very poor=3, terrible=4 
Abdominal pain  none=0, mild=1, moderate=2, severe=3  
Number of liquid stools per day  
Complications arthralgia, uveitis, erythema nodosum, pyoderma gangraenosum, aphthous 
ulcers, anal fissure, new fistula, abscess (score 1 per item) 
Palpable abdominal mass no=0, dubious=1, definite=2, definite and tender=3 
Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980;315:514. Reprinted with permission 
from Elsevier. 
 
 
Both the Oxford Index, based on one laboratory variable and nine clinical variables, and 
the Cape Town index, originally based on one laboratory variable and nine clinical 
variables, correlate with the CDAI (Myren et al. 1984, Wright et al. 1985, Sostegni et al. 
2003). Because the major contribution of subjective variables to the CDAI has attracted 
criticism, researchers have attempted to develop disease activity indices on objective 
grounds only. One instrument that eliminates subjective criteria is the van Hees or 
Dutch index; it is made up of two laboratory variables, of which serum albumin 
contributes most, and seven clinical features from patient history or physical 
examination (van Hees et al. 1980). Although the correlation between the van Hees index 
and the CDAI is poor, both seem to be predictive of CD exacerbations (Wright et al. 
1985). The CDAI describes poorly the activity of perianal and fistulizing CD; the 
perianal disease activity index (PDAI) currently represents the gold standard for 
evaluating perianal disease severity (Irvine 1995, Sostegni et al. 2003). Recently, the short 
CDAI was developed and validated (Thia et al. 2011). Of the eight variables in the 
CDAI, the short version includes only three that are clinical self-reported symptom 
variables. Though it shows a strong correlation with the CDAI, its self-reporting of 
subjective symptoms and well-being, means that it has disadvantages similar to those of 
the original index (Table 7).  
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Table 7. Clinical activity indices for Crohn’s disease. 
 
Clinical index Reference Variables Remarks 
    
CDAI Best et al. 1976  7 clinical, 1 laboratory: 
diarrhoea frequency, abdominal pain, 
general well-being, use of 
antidiarrhoeal medications, abdominal 
mass, extraintestinal features, 
haematocrit, weight 
 
Most used in clinical 
trials, time-consuming 
for clinical practice, 
necessitates a 7-day diary 
HBI Harvey and 
Bradshaw 1980  
5 clinical: 
diarrhoea frequency, abdominal pain, 
general well-being, abdominal mass, 
extraintestinal features 
 
Only clinical variables, 
no need for diary 
Oxford Index Myren et al. 1984  9 clinical, 1 laboratory: 
abdominal pain, diarrhoea/blood and 
mucus in stool, perianal involvement, 
fistulae, other complications, 
abdominal mass, tenderness, wasting, 
temperature, haemoglobin 
 
 
Cape Town 
index 
Wright et al. 1985  9 clinical, 1-2 laboratory: 
abdominal pain, stool consistency, 
well-being, complications (perianal or 
systemic), fever, abdominal mass, 
weight, temperature, haemoglobin 
 
ESR later added as a 
modification 
PCDAI Hyams et al. 1991  8 clinical, 3 laboratory: 
abdominal pain, diarrhoea, general 
well-being, weight, height, abdominal 
findings mass/tenderness, perirectal 
disease, extraintestinal manifestations, 
haematocrit, ESR, albumin 
 
For paediatric use 
van Hees index 
(Dutch index) 
van Hees et al. 1980  7 clinical, 2 laboratory: 
body mass index, abdominal mass, sex, 
temperature, stool consistency, 
previous resection, extraintestinal 
manifestations,  albumin, ESR 
 
Albumin plays an 
important role 
PDAI Irvine 1995  5 clinical: 
discharge of fistulae, pain/restriction 
of activities, restriction of sexual 
activity, type of perianal disease, degree 
of induration 
 
For assessment of 
perianal Crohn’s disease 
Short CDAI Thia et al. 2011  3 clinical: 
abdominal pain, diarrhoea frequency, 
general well-being. 
 
Necessitates a 7-day diary 
CDAI: Crohn’s disease activity index; HBI: Harvey-Bradshaw index; PCDAI: paediatric Crohn’s disease activity  
index; PDAI: perianal disease activity index; ESR: erythrocyte sedimentation rate 
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6.2 Endoscopic activity and mucosal healing 
In patients with long-standing chronic ileocolonic CD, correct diagnosis requires clear-
cut indications for endoscopy, assessment of disease activity and extension, dilation of 
strictures, and surveillance (Hommes and van Deventer 2004). Follow-up endoscopies 
are required when disease activity or disease location is uncertain. In CD, blood tests and 
symptoms do not necessarily correlate with endoscopic disease activity; intestinal 
inflammation can occur in patients free from symptoms (Cellier et al. 1994). 
Ileocolonoscopy has, however, several drawbacks: it is time-consuming and expensive, it 
requires bowel preparation, and most patients consider it unpleasant. 
Since the 1960s, clinical studies on UC have suggested a more favourable outcome after 
a corticosteroid course in UC patients achieving clinical and endoscopic remission than 
in those achieving only clinical remission. Up until the late 1990s, studies reported no 
such correlation in CD patients (Modigliani et al. 1990). The introduction of anti-TNF 
therapy completely changed investigators’ and clinicians’ attitudes towards mucosal 
healing; healing of the mucosa for the first time became possible. Since then, constantly 
growing interest in mucosal healing has revealed its clinical importance as a predictive 
marker of favourable outcome. Now, assessment of mucosal healing during therapy has 
become essential for clinical practice and for evaluation of response in clinical trials 
(Hommes and van Deventer 2004, Rutgeerts et al. 2007).  
 
6.2.1  Anti-TNF therapy and mucosal healing 
Schnitzler and coworkers (2009) analysed retrospectively for a median of almost five 
years 214 CD patients who had undergone endoscopy before start of infliximab therapy. 
Scheduled infliximab therapy led to mucosal healing that was associated with the best 
long-term outcome; nearly 80% showed sustained clinical benefit from infliximab until 
the end of the study. Those achieving mucosal healing underwent significantly less 
surgery and needed less hospital treatment than did those with active disease seen in the 
follow-up endoscopy done approximately seven months after the start of therapy. In 
IBD, studies and reviews suggest mucosal healing as a therapeutic goal, with absence of 
mucosal ulcerations serving in most anti-TNF trials as the definition of mucosal healing 
(Rutgeerts et al. 2006, 2012, Frøslie et al. 2007, Isaacs 2010, Neurath and Travis 2012). 
The importance of minor changes such as an aphthous ulcer in otherwise healed mucosa 
remains unclear, however. 
Most studies on predictive factors in anti-TNF-treated CD have focused on clinical 
outcome. We know relatively little about factors predicting mucosal healing during anti-
TNF therapy. In 201 Hungarian CD patients treated with adalimumab, Kiss and 
coworkers (2011) found that low CRP (<10 mg/l) at week 12, clinical remission at week 
24, and non-smoking were all associated with endoscopic improvement or healing at one 
year. They defined clinical remission as CDAI<150, and mucosal healing as the absence 
of any mucosal lesions or signs of active inflammation. Hébuterne and coworkers (2013) 
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have described the similarity of endoscopic findings in early endoscopic evaluation and 
in endoscopy one year after start of anti-TNF. Their open-label MUSIC trial involved 89 
CD patients treated with certolizumab pegol for 54 weeks. They defined endoscopic 
response as a decrease in CDEIS score of more than 5, defined maintenance of 
endoscopic effect as unaltered CDEIS between weeks 10 and 54, and defined complete 
endoscopic remission as CDEIS<3. In a subpopulation of 52 patients with 54-week 
endoscopic data, of the 37 who showed an endoscopic response at 10 weeks, 28 (76%) 
maintained their response at week 54. Of 7 patients in complete endoscopic remission at 
week 10, 5 (71%) maintained remission at week 54.  
Although the EXTEND trial focused mainly on comparing endoscopic outcome after 
adalimumab or placebo following a two-week adalimumab induction, its results also 
suggested that mucosal healing may be more difficult to achieve for patients with more 
severe ulcerations at baseline (Rutgeerts et al. 2012). 
Optimal timing for determination of mucosal healing remains unsettled (Neurath and 
Travis 2012). Recently, the concept of deep remission, defined as a combination of 
clinical and endoscopic remission, has become recognized as a potential predictive CD 
marker (Rutgeerts et al. 2009, 2012, Hommes et al. 2012, Travis et al. 2012). During 
adalimumab therapy, deep remission has been associated with lower health-care costs 
and a favourable long-term outcome in terms of hospitalizations and quality of life 
(Colombel et al. 2011). The definition of deep remission is, however, still evolving. 
 
6.3 Endoscopic scoring of inflammatory activity 
The need for reproducibility and standardisation in the management and follow-up of 
IBD has led to development of several endoscopic grading scores. Endoscopic scores 
originally classifying disease activity have also been proposed as means to define mucosal 
healing (Hommes and van Deventer 2004).  
 
6.3.1  CDEIS 
The Crohn’s disease endoscopic index of severity (CDEIS) was developed at the end of 
the 1980s by the French Groupe d’Etude des Affections Inflammatoires Digestivesis 
(GETAID) (Mary and Modigliani 1989). The CDEIS is validated in terms of 
reproducibility and global endoscopic evaluation of lesion severity and has become the 
gold standard for assessment of endoscopic activity in CD (Sostegni et al. 2003). 
Calculation of the CDEIS requires considering the colon and the terminal ileum as 
comprising five segments: (1) rectum, (2) left colon and sigmoid, (3) transverse colon, (4) 
right colon, and (5) ileum (Table 8). 
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Table 8. Crohn’s disease endoscopic index of severity (CDEIS) 
 
 Rectum  Sigmoid 
and left 
colon 
 
Transverse 
colon 
 Right 
colon 
 Ileum   
Deep ulceration  
quote 12 if present in 
the segment, 0 if absent 
__ + __ + __ + __ + __ = Total 1 
Superficial ulceration  
quote 12 if present in 
the segment, 0 if absent 
__ + __ + __ + __ + __ = Total 2 
Surface involved by 
disease measured in 
cm* 
__ + __ + __ + __ + __ = Total 3 
Ulcerated surface  
measured in cm* 
__ + __ + __ + __ + __ = Total 4 
Total 1 + Total 2 + Total 3 + Total 4 = Total A 
Number (n) of segments totally or partially explored (1–5)  n 
Total A divided by n = Total B 
Quote 3 if ulcerated stenosis anywhere, 0 if not = C 
Quote 3 if non ulcerated stenosis anywhere, 0 if not = D 
Total B + C + D = CDEIS 
*For partially explored segments and for the ileum, the 10 cm linear scale represents the surface effectively explored 
Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective 
multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 
1989;30:983-989. Reproduced with permission from BMJ Publishing Group Ltd. 
 
 
From each segment, the presence of nine mucosal lesion types would be recorded: (1) 
pseudopolyp, (2) healed ulceration, (3) erythema (plaques, bands, or diffuse), (4) swollen 
mucosa, (5) aphthous ulceration, (6) superficial or shallow ulceration, (7) deep ulceration, 
(8) non-ulcerated stenosis, and (9) ulcerated stenosis. The percentage of segmental 
surfaces involving the disease and ulcerations are posited on a 10-cm analogue scale 
between 0 and 10 (no lesion=0, lesions or ulcerations involving 100% of the 
segment=10). For the terminal ileum and for those colonic segments only partly 
explored, the 10-cm scale represents the area actually seen. The CDEIS can range 
between 0 and 44, with higher scores depicting more severe endoscopic activity. 
Although the CDEIS has served for endoscopic scoring in several studies, threshold 
values for remission or for mild, moderate, or severe disease, or for significant response 
are still lacking. After revisiting the endoscopy findings for the validation of the CDEIS, 
the GETAID study group suggested a cut-off value of 3 or 3.5 for complete mucosal 
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healing, defined as no lesions or scars, and a rougher cut-off for endoscopic remission 
set at CDEIS levels of between 6 and 7, defined as no lesions or scars but accepting 
minor lesions, and for endoscopic response a decrease in the CDEIS of more than 5 
(Mary et al. 2005, 2006). The CDEIS correlates poorly with clinical activity (Cellier et al. 
1994).  
 
6.3.2  SES-CD 
The time-consuming and complex structure of the CDEIS has prevented it from 
becoming a tool in everyday clinical practice. To simplify endoscopic assessment of 
inflammatory activity in CD, the simple endoscopic score for Crohn’s disease (SES-CD) 
was developed and validated nearly ten years ago. Its construction and validation is based 
on correlations with the CDEIS and, to a lesser extent, the CDAI (Daperno et al. 2004). 
The SES-CD shows a strong correlation with the CDEIS and is easier and quicker to 
calculate. It is based on four variables scored in the same five ileocolonic segments as in 
the CDEIS (Table 9). The ileum is scored for the full extent to which it is examined, but 
the ileal score specifically excludes the ileocaecal valve or any ileocolonic anastomosis, 
which are both included in the neighbouring distal segment. Additionally to the 
ileocaecal valve, the right colon includes the caecum and the ascending colon up to the 
hepatic flexure. The transverse colon is defined as the segment between the hepatic and 
splenic flexures. The left colon includes the descending colon and sigmoid colon. The 
rectum is defined as that portion distal to the rectosigmoid junction. The SES-CD can 
range from 0 to 60, with higher scores for increased inflammatory activity. No consensus 
on cut-offs for remission or different stages of inflammatory activity exists. Suggested 
definitions on endoscopic remission for the SES-CD have been a score of 0–2 and 0–3 
(Sipponen et al. 2008a, Schoepfer et al. 2010). Moskovitz and coworkers (2007) defined 
remission as an SES-CD score of 0–2, mild inflammation as 3–6, moderate 
inflammation as 7–15, and severe inflammation as ≥16. Because variables of each 
segment of the colon are noted separately before calculation of the total score, minor 
changes covering several segments may give a higher CDEIS or SES-CD. Thus, it seems 
that both endoscopic scores overestimate colonic disease and underestimate ileal disease, 
or severe but limited inflammation in one colonic segment (Sipponen et al. 2010a). 
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Table 9. The simple endoscopic score for Crohn’s disease (SES-CD)  
 
 Values 
Variable 0 1 2 3 
Size of ulcers none 
aphthous ulcers 
(<0.5 cm) 
large ulcers 
(0.5–2.0 cm) 
very large ulcers 
(>2.0 cm) 
Ulcerated surface none <10% 10–30% >30% 
Affected surface unaffected <50% 50–75% >75% 
Presence of narrowing none 
single, can be 
passed 
multiple, can be 
passed 
cannot be passed 
Total SES-CD: Sum of the values of each variable and for every examined bowel segment (rectum; left 
colon and sigmoid; transverse colon; right colon; ileum). 
Daperno M, D'Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity 
score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60:505-512. Reprinted with permission from 
Elsevier. 
 
 
6.3.3  Other scores 
Following curative resection of CD, endoscopic assessment reveals signs of 
inflammatory activity in up to 70% of patients at 6 to 12 months, and the severity of the 
lesions predicts subsequent clinical course (Rutgeerts et al. 1990). The Rutgeerts score, 
developed in 1990 for assessment of ileal disease, is considered the gold standard for 
endoscopical post-surgical recurrence evaluation (Sostegni et al. 2003). Findings in the 
ileum are scored in five categories; i0: no lesions occur in the distal ileum; i1: ≤5 
aphthous lesions; i2: >5 aphthous lesions with normal mucosa between the lesions, or 
skip areas of larger lesions or lesions restricted to ileocolonic anastomosis; i3: aphthous 
ileitis with diffusely inflamed mucosa; and i4: diffuse inflammation with large ulcers, 
nodules, or narrowing (Rutgeerts et al. 1990). 
Recent studies have used confocal laser endomicroscopy for in vivo assessment of 
mucosal inflammatory activity in IBD. The Crohn’s Disease Endomicroscopy Activity 
Score (CDEAS) is capable of detecting colonic segments without any macroscopic 
inflammation that show histological and endomicroscopical evidence of inflammation, 
enabling discrimination between quiescent CD and normal mucosa in healthy controls 
(Neumann et al. 2012). The score represents the first endoscopic index for CD based on 
in vivo histology but still needs validation. Another endomicroscopic grade, the Watson 
grade, is based on cell shedding seen in endomicrosopy, and enables assessment of local 
barrier dysfunction in vivo. In patients with complete mucosal healing as defined by 
conventional white light endoscopy, increased cell shedding has been associated with 
subsequent relapse within 12 months after endomicroscopic examination (Kiesslich et al. 
2012).  
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The drawbacks of endoscopic scores are their inability to assess transmural injury, the 
penetrating nature of the disease, signs of progression, and structural damage. For 
example, the clinical activity scores and the endoscopic scores can be similar both in CD 
patients with recent disease onset who are naïve to treatment, and in patients with a long 
history of disease who have extensive, irreversible bowel damage from progressive 
inflammation or previous bowel resection. Therefore, the concept of cumulative bowel 
damage has evolved, and it has been included in a newly developed index called the 
Lémann score, or the Crohn’s disease digestive damage score (Pariente et al. 2011). This 
score aims to identify CD patients at risk for rapid damage progression who would 
benefit from early introduction of immunosuppressive or anti-TNF therapy. It is a 
complex score evaluating strictures and penetrating lesions as well as surgical resection 
or bypass of the bowel in the whole GI tract. Additionally to medical history and 
conventional endoscopy, it requires imaging for assessment of transmural damage. The 
Lémann score ranges from 0 (no inflammation, no damage) to a theoretical value of 10 
(complete resection of the GI tract). 
 
6.4 Histological activity 
Several clinical drug trials have shown that medical treatment can alter mucosal 
histology, promoting healing and normalisation of the mucosa (D'Haens et al. 1997, 
1999a, b, Geboes et al. 2005). However, due to the patchy character of the disease, 
including sample error and the fact that the terminal ileum may be the only area affected, 
no general agreement exists among experts as to the value of microscopy in assessing 
CD activity (Van Assche et al. 2010a). Assessment of histologic disease activity cannot 
therefore in general be recommended as a treatment endpoint in clinical trials (Sandborn 
et al. 2002).  
 
6.5 Blood tests 
In IBD, anaemia, elevated white blood cells, and increased platelet count are common 
but nonspecific laboratory findings (Cellier et al. 1994). ESR indirectly measures acute-
phase plasma protein concentrations. In addition to inflammation, any condition that 
elevates fibrinogen: pregnancy, diabetes mellitus, end-stage renal failure, heart disease, or 
malignancy, may also elevate the ESR. ESR is slowly responsive to changes in 
inflammatory status. In CD, ESR appears to rise with increasing inflammatory activity in 
colonic disease, but fails to reflect disease activity of the small intestine (Sachar et al. 
1990, Desai et al. 2007).  
CRP is an acute-phase protein produced by the liver in response to tissue damage due to 
inflammation, infection, or injury; high CRP level indicates active disease or some 
bacterial complication. CRP, the most studied of all laboratory markers, has exhibited 
the best overall performance. Regrettably, its correlation with CD activity has been 
 36 
 
inconsistent (Andre et al. 1981, Brignola et al. 1986, Boirivant et al. 1988, Niederau et al. 
1997). A proportion of patients with mildly active disease seem to systemically present 
with low CRP values, which some suggest is a consequence of genetic polymorphism 
(Carlson et al. 2005). High sensitivity CRP (hsCRP) may be a more sensitive method of 
detecting low-grade inflammatory luminal disease than is standard CRP, but more data 
are necessary before hsCRP can be implemented in routine clinical use (Jones et al. 
2008). In CD, albumin correlates inversely with clinical and endoscopic activity. 
Hypoalbuminaemia may be a consequence of protein loss from the inflamed gut or may 
result from malnutrition secondary to inadequate protein intake or malabsorption 
(Modigliani et al. 1990, Vermeire et al. 2006). 
 
6.5.1  Cytokines and serological biomarkers 
As an immunologic response, TNFα is primarily produced by activated macrophages 
and monocytes. Serum TNFα is often increased in IBD, but as the serum concentrations 
are not consistently elevated, their value as surrogate markers of IBD activity is limited 
(Desai et al. 2007). Elevated levels of several other serum cytokines and cytokine 
receptors such as IL-1β, IL-2, IL-2R, IL-6, IFN-γ, IL-8, IL-23, IL-27, and IL-15 have 
been apparent in IBD, but these seem to have limited utility as non-invasive markers of 
disease activity; despite active IBD serum levels frequently remaining low (Reimund et al. 
1996, Reinisch et al. 1999, Desai et al. 2007).  
Because ASCA levels are fairly stable over time, these markers are of limited value in 
monitoring CD activity. During anti-TNF therapy, antibody responses in most CD 
patients to ASCA, pANCA, anti-I2, and anti-ompC seem also to remain unchanged 
(Landers et al. 2002, Papp et al. 2007). 
 
6.5.2  Radio-labelled neutrophils 
White-cell scans with radio-labelled leukocytes or granulocytes can be helpful in 
detecting acute inflammation. Abdominal scintigraphy and four-day faecal collection of 
111Indium-labeled granulocytes is a specific, sensitive, and quantitative method that 
enables intestinal inflammatory activity assessment. In CD, this technique has been 
suggested as the gold standard for assessing intestinal inflammation (Saverymuttu et al. 
1985, Gaya and Mackenzie 2002). In CD patients free from symptoms, it may also detect 
subclinical mucosal inflammation (Saverymuttu 1986). Because this procedure requires 
special labelling facilities, it is expensive; in addition, it exposes patients to radiation, and 
its use in clinical practice is limited. 
 
6.6 Intestinal permeability tests 
In CD, intestinal permeability is increased and correlates with inflammatory changes in 
the small bowel mucosa. It can be assessed non-invasively by measurement of the 
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urinary secretion of orally administered test substances. Two such substances based on 
differing renal excretion rates, when combined, give a specific index of intestinal 
permeability. Most standard test substances comprise a combination of a disaccharide 
such as lactulose and a monosaccharide (L-rhamnose or mannitol). Other substances 
include 51Chromium-ethylene diamine tetra-acetic acid (51Cr-EDTA), 99Technetium-
diethylene triamine penta-asectic acid (99Tc-DPTA), polyethylene glycol (PEG), and 
iohexol (Bjarnason et al. 1995, Halme et al. 2000). Lactulose-mannitol and iohexol tests 
have correlated with endoscopic and clinical CD activity (Halme et al. 2000). In CD, 
increased intestinal permeability during remission demonstrably precedes relapse in CD 
(Wyatt et al. 1997). However, permeability tests are non-specific for IBD, and their 
diagnostic accuracy in discriminating IBD from non-IBD conditions is inferior to the 
accuracy of faecal inflammatory markers (Canani et al. 2006). 
 
6.7 Faecal tests 
Active bowel inflammation is associated with leukocyte infiltration and the production 
of acute-phase proteins in the mucosa. Because the faecal stream is in direct contact with 
the intestinal mucosa, hypothetically it should contain specific markers of mucosal 
disease, ones consistent with the presence and severity of inflammation. Potential faecal 
biomarkers include faecal excretion of leukocytes, leukocyte products, and serum 
proteins (Desai et al. 2007). The instability of inflammatory markers in the stool has 
traditionally led to difficulty in accurately assessing inflammatory products in the stool. 
The presence of faecal white cells—after exclusion of infection—may prove a useful 
indicator of gut inflammation. The accuracy of this marker depends, however, on rapid 
examination of the stool sample before degradation of white cells by gut bacteria. Levels 
of α-1-antitrypsin and proteins released from neutrophils such as myeloperoxidase have 
also served as inflammatory markers for IBD, but their inadequate accuracy in 
distinguishing active IBD from healthy controls has prevented their use in clinical 
practice. Furthermore, comparison of faecal excretion of α-1-antitrypsin with that of 
111In-labelled leukocytes has showed an inconsistent correlation (Fischbach et al. 1987, 
Crama-Bohbouth et al. 1989). 
Several of the S100-family proteins correlate well with intestinal inflammation, 
particularly faecal calprotectin, which has a positive predictive value of 85 to 90% in 
distinguishing IBD from IBS (Tibble et al. 2000a, Kane et al. 2003, D'Inca et al. 
2007). Their concentrations in stool also correlate with both endoscopic and histologic 
disease activity in patients with IBD, so the potential exists to replace endoscopy with 
stool tests to assess mucosal healing during medical therapy and also to predict 
probability of relapse. However, with their small population sizes and differing 
definitions of mucosal healing, studies on faecal biomarkers have been unable to define 
clear-cut points for mucosal healing (Lewis 2011). 
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6.7.1  Calprotectin 
Calprotectin, a heterocomplex of S100A8 and S100A9 with a molecular mass of 36.5 
kDa, is a calcium- and zinc-binding protein derived predominantly from neutrophils, and 
to a lesser extent, from monocytes and reactive macrophages. It comprises up to 60% of 
the cytosolic protein in human neutrophils (Fagerhol et al. 1980). Due to its good 
resistance to bacterial degradation, calprotectin shows excellent stability in faeces. In 
IBD, it correlates strongly with excretion of 111indium-labeled granulocytes and has also 
repeatedly correlated with both endoscopic and histological findings. A normal 
calprotectin concentration has been a useful surrogate marker for endoscopically and 
histologically inactive disease (Roseth et al. 1999, Jones et al. 2008, Sipponen et al. 2008a, 
2010b, Schoepfer et al. 2010).    
Calprotectin can be quantified from faeces by several different enzyme-linked 
immunosorbent assays (ELISAs). The original quantitative ELISA developed by Roseth 
and coworkers (1992) was improved in 2000, when its units were changed from mg/l to 
μg/g (Tibble et al. 2000a). The ELISA test is the most widely used measure of faecal 
calprotectin concentration. In one study comparing commercial quantitative ELISAs, 
only small differences were detectable, and all assays tested were considered suitable for 
routine laboratory measurement of faecal calprotectin (Whitehead et al. 2013). 
Limitations of the ELISA test are that it is time-consuming and requires a laboratory and 
trained personnel. In addition, collection of multiple samples is necessary to make the 
running test more cost-effective. As a consequence, rapid point-of-care tests have 
recently appeared, two of which are a semi-quantitative assay and a rapid quantitative 
test. These chromatographic immunoassay tests rely on lateral flow assay technology in 
which the centrifugation step can be omitted (Damms et al. 2008). The rapid quantitative 
test has shown accuracy similar to that of ELISA in detecting endoscopic activity and 
postoperative recurrence (Lobatón et al. 2013).  
 
The remitting and relapsing course of both CD and UC is unpredictable. Estimating 
relapse risk to enable preventive or early treatment would require an accurate marker. In 
IBD, one useful predictor of mucosal healing has been low faecal calprotectin level, 
whereas high calprotectin levels may indicate risk for clinical relapse during clinical 
remission (Tibble et al. 2000b, Roseth et al. 2004, Sipponen et al. 2008b, Mao et al. 2012). 
Calprotectin as a predictor of long-term outcome in anti-TNF-treated CD is, however, 
insufficiently investigated. In a study of patients receiving infliximab induction therapy 
followed by single immunomodulator maintenance therapy, postinduction calprotectin 
levels failed to predict clinical relapse at one year (Laharie et al. 2011). Open questions 
also exist regarding calprotectin as a marker of intestinal inflammation. Most studies on 
calprotectin reference values focus on distinguishing IBD from IBS or from healthy 
controls, but the calprotectin cut-off value for distinguishing IBD from IBS is not 
necessarily identical to the calprotectin cut-off for distinguishing active IBD from 
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quiescent IBD. Reference values for an acceptable calprotectin level might even differ 
depending on type of IBD: one suggestion is that calprotectin concentrations depend on 
the inflamed bowel segment, with higher concentrations of calprotectin occurring in CD 
with colonic involvement, but one recent study was unable to confirm this (Sipponen et 
al. 2008c, Schoepfer et al. 2010, Jensen et al. 2011). Additionally, in a population of 
patients with mild to moderate clinical activity, considerable intraindividual variance in 
calprotectin concentrations in stool samples appeared (Moum et al. 2010).  Thus, despite 
the frequently used cut-off values of <50 μg/g or <100 μg/g for calprotectin to 
distinguish between active and inactive CD, the optimal cut-off value for endoscopic 
remission in CD is still unestablished (von Roon et al. 2007, Sipponen et al. 2008c, Lewis 
2011) (Table 10). 
 
 
Table 10. Studies investigating the power of faecal calprotectin distinguishing 
endoscopic remission and endoscopically active disease.  
Reference 
Patients or 
endoscopies Endoscopic definition 
Sensi-
tivity 
% 
Speci-
ficity 
% 
F-Calpro 
cut-off 
μg/g 
      
D'Inca et al. 2007  31 Inactive disease: 
modification of SES-CD=0 
81 80 80 
Sipponen et al. 2008c 77 Active disease: CDEIS≥3 
 
91 
81 
70 
44 
69 
92 
50 
100 
200 
Langhorst et al. 2008 43 No inflammation: No 
visible inflammation in 
endoscopy 
81 80 48*  
Schoepfer et al. 2010 140 Active disease: 
SES-CD≥4 
89 
89 
58 
72 
50 
70 
D'Haens et al. 2012 87 Remission: CDEIS 0–3 94 62 250 
Lobatón et al. 2013 37 
111 
Remission: CDEIS 0–3 
No ulcers vs. ulcers 
76 
68 
97 
84 
274 
283 
F-Calpro: faecal calprotectin 
*μg/ml 
 
 
6.7.2  S100A12, lactoferrin, and polymorphonuclear neutrophil elastase 
S100A12, also known as calgranulin C, is expressed as a cytoplasmic protein in 
neutrophils and has pro-inflammatory properties (Foell et al. 2003). It activates the 
nuclear factor-ΚB signal transduction pathway, upregulating TNFα and further 
enhancing S100A12 expression (Hofmann et al. 1999). These properties are relevant to 
IBD, with infiltration of S100A12-positive polymorphonuclear cells potentially 
contributing to the invasion of other leukocytes (Leach and Day 2006). This may suggest 
that S100A12 contributes to the processes of intestinal inflammation (de Jong et al. 
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2006). S100A12 is evenly distributed in faeces and is stable despite temperature changes 
for seven days, characteristics suitable for a non-invasive, stool-based disease marker. In 
predicting small bowel inflammatory changes, S100A12 shows moderate specificity but 
low sensitivity (Sipponen et al. 2012). According to one study, faecal S100A12 correlates 
better with intestinal inflammation than does faecal calprotectin or other biomarkers. In 
distinguishing active IBD from IBS, S100A12 sensitivity was 86%, and specificity was 
96%, superior to the sensitivity (63%) and specificity (86%) of calprotectin (Kaiser et al. 
2007). The role of S100A12 as a predictive marker has not yet been established. 
Lactoferrin, an iron-binding glycoprotein secreted by most mucosal membranes that 
interact directly with external pathogens, is detectable in saliva, tears, vaginal secretions, 
faeces, synovial fluid, and mammalian breast milk. It is a major component of the 
secondary granules of polymorphonuclear neutrophils, which are a primary component 
of the acute inflammatory response (Baynes and Bezwoda 1994, Kayazawa et al. 2002). 
In the intestinal lumen, during inflammation, with its influx of neutrophils, faecal 
lactoferrin levels quickly increase (Desai et al. 2007). Having antibacterial activity and 
being resistant to proteolysis in the faeces, lactoferrin may remain stable in stool for as 
long as five days compared with seven days for calprotectin (Sugi et al. 1996). Several 
studies indicate the usefulness of measuring lactoferrin in patients with IBD (Kane et al. 
2003). Although most have reported similar sensitivities and specificities for both 
lactoferrin and calprotectin in differentiating chronic IBD from IBS, some studies also 
indicate that lactoferrin’s performance would be slightly inferior to that of calprotectin 
(Silberer et al. 2005).  
Polymorphonuclear neutrophil elastase (PMN-e) is a neutral proteinase normally stored 
in the azurophil granules of polymorphonuclear neutrophils but released by activation of 
these cells as a mediator of inflammation. It has proved its clinical value as a test for 
pancreatic exocrine dysfunction, but it may also play a role in IBD in assessing disease 
activity (Poullis et al. 2002). In a study both of UC and of CD patients comparing three 
stool markers with endoscopic findings, CRP and the clinical indices calprotectin, 
lactoferrin, and PMN-e were all able to differentiate between active IBD and inactive 
IBD and also to distinguish IBD from IBS. Although the PMN-e levels were 
significantly higher in active than in inactive IBD, and all three faecal markers were 
superior to CRP and the CDAI in their diagnostic accuracy, calprotectin seemed to have 
the highest accuracy for CD (Langhorst et al. 2008). 
 
6.8 Combined activity scores 
Global assessment of CD activity requires a combination of clinical observation, 
laboratory and endoscopy findings, and in certain situations, radiological imaging. 
Attempts to successfully combine different noninvasive laboratory tests and clinical 
findings and symptoms to assess the presence or absence of endoscopically determined 
inflammation are rare. Langhorst and coworkers (2008) studied the performance of the 
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CDAI, CRP, calprotectin, lactoferrin, and PMN-e in discriminating between active and 
inactive inflammation in 43 CD patients. Inactive inflammation was defined as the 
complete absence of inflammatory lesions in all observable segments of the colon and 
terminal ileum. Clinical examination and contrast-enhanced magnetic resonance imaging 
of the small bowel excluded extraintestinal and small bowel involvement. Their 
comprehensive activity index was rated positive when it met at least two of three 
conditions: elevation of at least two stool values, elevated CRP, and elevated CDAI. 
CRP>7 mg/l and CDAI>80 were considered elevated, whereas stool samples were 
elevated based on optimized cut-off values: calprotectin>48 µg/ml, lactoferrin>7.05 
µg/ml, PMN-e≥0.062 µg/ml. Sensitivity for this categorical index was 79% and 
specificity 70%, these values being superior to those of both CRP and the CDAI, but 
still inferior to calprotectin (sensitivity 82%, specificity 80%).  
 
6.9 Tools for assessing efficacy of anti-TNF therapy in CD 
Studies of patient- and disease characteristics predicting a response in anti-TNF-treated 
CD have generally been based on clinical data (Vermeire et al. 2002, Arnott et al. 2003, 
Orlando et al. 2012). Despite extensive research on various tests of disease activity in 
luminal CD, in randomised controlled trials investigating the efficacy of anti-TNF, the 
primary endpoint by far the most studied has been clinical response or remission 
(Hanauer et al. 2002, Sandborn et al. 2007). Mucosal healing as an endpoint has only 
recently been included in larger studies (Rutgeerts et al. 2012). As for CRP, faecal 
calprotectin, or radiology, studies are limited to the observational, are post hoc, or are very 
small (Sipponen et al. 2008b, Kiss et al. 2011, Reinisch et al. 2012 Van Assche et al. 2013) 
(Table 11). 
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Table 11. Tools for assessing and predicting response of anti-TNF therapy in 
luminal Crohn’s disease. 
Tool Reference Variables Remarks 
History 
Vermeire et al.  2002, 
Parsi et al. 2002, 
Arnott et al. 2003, 
Orlando et al. 2012 
Smoking worsens both clinical and 
endoscopic response, older age and 
history of surgery are associated with 
worse clinical response, isolated 
colonic disease is associated with 
better response 
Mostly clinical outcome 
studied 
Clinical 
activity 
Hanauer et al. 2002, 
Sandborn et al. 2007, 
Kiss et al. 2011, 
CDAI <150 (or ≤150) or drop of 
CDAI >70 or >100 
By far the most studied 
endpoint in anti-TNF 
trials 
Endoscopic 
findings 
Scnitzler et al. 2009,  
Rutgeerts et al. 2012, 
Hébuterne et al. 2013 
―No ulcers‖ or CDEIS <3 or decrease 
of CDEIS >5  
No established cut-off in 
clinical practice 
Stool 
markers 
Sipponen et al. 2008b 
Decline of faecal calprotectin and 
lactoferrin levels between baseline and 
3 months 
No established cut-off in 
clinical practice 
CRP 
Kiss et al. 2011,  
Reinisch et al. 2012 
Low CRP <10 at 24 weeks or CRP 
normalisation at week 14 
High baseline levels 
enhance the probability 
of maintaining remission 
Radiology Van Assche et al. 2013 
Decrease in wall thickening at week 2 
or 26 
Only 20 patients 
included 
Anti-TNF:  anti-tumour necrosis factor-α antibodies; CRP: C-reactive protein; CDAI: Crohn’s disease 
activity index; CDEIS: Crohn’s disease endoscopic index of severity 
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AIMS OF THE STUDY 
Endoscopic resources are limited, and no consensus exists on optimal timing for 
assessment of anti-TNF therapy response in CD patients. The aims of the present study 
of patients with active luminal CD were to  
1.  evaluate the role of endoscopic assessment and non-invasive markers of disease 
activity in predicting long-term endoscopic response to anti-TNF therapy (Studies 
I to III). 
2. evaluate the power of non-invasive markers of disease activity alone and in 
combination as a replacement for endoscopy (Study IV). 
3. develop a non-invasive combination score of disease activity markers to reduce 
need for endoscopy (Study IV). 
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PATIENTS AND METHODS 
1 IBD-HOT study 
The main aim of the IBD-HOT (Inflammatory Bowel Disease–Health Outcome of 
Treatment) observational study at the Division of Gastroenterology, Helsinki University 
Central Hospital, was to assess the use, efficacy, and safety of strong 
immunosuppressants and anti-TNF in patients with CD and UC. This would allow the 
construction of a systematic follow-up tool in the form of a register for surveillance of 
patients with severe disease. The study consisted of two phases: one retrospective, with 
data on all IBD patients treated with strong immunosuppressants and infliximab 
between 1999 and the end of 2006, and a prospective three-year observational follow-up 
study including all IBD patients scheduled for treatment with strong 
immunosuppressants or with anti-TNF between January 2007 and December 2010. The 
patients were treated according to standard clinical routines by gastroenterologists at the 
Division of Gastroenterology; study participation affected neither treatment nor choice 
of medication. Retrospectively collected data were available for 148 IBD patients and 
prospectively collected data for 212 IBD patients. 
 
2  Patients 
2.1 Retrospective studies (I, III) 
2.1.1 Patients in Study I 
This study was based on a retrospectively constructed medical database collated from a 
register of all consecutive patients with IBD who were treated with infliximab between 
1999 and the end of 2006. For the study, 71 CD patients (35 female, 49%) fulfilled the 
following inclusion criteria: infliximab-treated active luminal ileitis, colitis, or ileocolitis, 
and their data on endoscopy at baseline and 3 months after start of treatment. Exclusion 
criteria were isolated fistulizing disease, isolated stricturing disease, and upper GI 
involvement. CD diagnosis was based on standard clinical, endoscopic, radiological, and 
histological criteria. The Montreal classification served for CD classification; 51 patients 
had pure inflammatory disease and 20 patients had inflammatory disease complicated 
with strictures or fistulae (Satsangi et al. 2006). All patients presented with moderate to 
very severe luminal inflammation as determined by endoscopy. Analysis was of the 
outcome of the first infliximab therapy given for each patient.  
 
2.1.2 Patients in Study III 
Study III comprised retrospectively analysed data from 60 IBD patients (34 CD, 26 UC) 
from both the retrospective and prospective parts of the IBD-HOT study, treated for 
active luminal disease with anti-TNF (infliximab or adalimumab) between April 2005 
and April 2010. All patients had elevated faecal calprotectin levels at baseline and had 
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data available on calprotectin after induction with anti-TNF. Of the 34 CD and 26 UC 
patients, 15 and 19, respectively, were female. For induction, patients received either 
infliximab (26 UC and 16 CD patients, 5 mg/kg at weeks 0, 2, 6, or at weeks 0, 8), or 
adalimumab (18 CD patients, 160 and 80 mg given at weeks 0 and 2, followed by 40 mg 
every other week, or 80 mg at week 0, followed by 40 mg every other week for 8–12 
weeks). After the induction therapy, anti-TNF was continued in all patients with 
endoscopic or clinical response as scheduled maintenance therapy for at least one year if 
no relapse occurred earlier.  
 
2.2 Prospective studies (II, IV) 
2.2.1  Patients in Study II 
This study included data collected between January 2007 and December 2010 on 42 
patients (20 female, 48%) followed up for approximately one year from start of anti-
TNF therapy. All patients had endoscopy-verified active, ongoing luminal CD at baseline 
and received treatment for at least 3 months with anti-TNF. More than half the patients 
(52%) had a history of bowel surgery due to CD complications. The patients received 3-
month induction therapy with either infliximab or adalimumab. Standard induction 
therapy with adalimumab was 160 and 80 mg given subcutaneously at weeks 0 and 2, 
followed by 40 mg given every other week, and with infliximab 5 mg/kg given 
intravenously at weeks 0, 2, and 6. Three months after start of anti-TNF, all patients 
underwent follow-up endoscopy. Patients with an endoscopic or clinical response 
continued anti-TNF as maintenance therapy administered as adalimumab 40 mg every 
other week or infliximab 5 mg/kg every 8 weeks. All patients had data either on 
endoscopy obtained approximately one year from start of anti-TNF, or had data on 
bowel surgery performed between 3 months and roughly one year from start of anti-
TNF.  
 
2.2.2  Patients in Study IV 
Of those 109 patients with endoscopically documented active luminal CD receiving anti-
TNF therapy (either infliximab or adalimumab) between January 2007 and December 
2010, we identified 64 (32 female, 50%) with data both on the SES-CD and on at least 
one other non-invasive disease-activity-measuring approach, obtained within 28 days 
from endoscopy. Only endoscopy examinations with complete data on all existing bowel 
segments were included; if a stricture impeded the endoscopist in scoring a proximal 
bowel segment, the endoscopic assessment was excluded. Patients with isolated upper 
GI disease were also excluded. Because  many patients underwent more than one 
endoscopic assessment, data covered 210 endoscopies. Patients were on anti-TNF 
therapy during 124 endoscopic assessments. 
Table 12 summarises basic data of all four studies performed. 
 46 
 
Table 12. Basic data from Studies I-IV 
 
Study Study nature and main aims Patients, n Remarks 
I Retrospective evaluation of early endoscopy as 
a predictor for long-term endoscopic response 
71 Similar 
construction and 
objective in 
Studies I and II II 
Prospective evaluation of early endoscopy as a 
predictor for long-term endoscopic response 
42 
III Retrospective study of early faecal calprotectin 
as a predictor for long-term clinical response 
60 34 CD patients 
26 UC patients 
IV Prospective study of surrogate markers of 
endoscopic activity 
64 210 endoscopies 
CD: Crohn’s disease; UC: ulcerative colitis 
 
 
3 Methods 
3.1 Endoscopic scoring 
In Study I, scoring of CD activity was retrospective. We reassessed the endoscopy 
reports and their six or more colour prints of the findings. The scoring itself was 
unblinded, and scores were based on the consensus of two experienced specialists (U.N., 
U.T.). Inflammatory activity was graded according to mucosal activity in the most-
affected area as: 0: remission; 1–2: very mild or mild inflammatory activity (light mucosal 
erythema or granularity or aphthous inflammation, without ulcerations); 3–4: moderate 
activity (superficial ulcerations); 5–6: severe or very severe activity (deep ulcerations, with 
a diameter of under or over 2 cm). The criterion for a positive endoscopic response 
was—somewhat arbitrarily—a decrease from baseline in endoscopic score of at least two 
points. As the definition of mucosal healing can range from normal endoscopic findings 
to light mucosal erythema or granularity without ulcerations (Frøslie et al. 2007), it was 
determined in Study I as a mucosal activity score of 0–2.  
In Studies II, III, and IV, CD inflammatory activity was scored according to the SES-
CD (Daperno et al. 2004). An SES-CD score of 0–2 was defined as remission, 3–6 as 
mildly active disease, 7–15 as moderately active disease, and ≥16 as severely active 
disease, based on Moskovitz and coworkers (2007). Additionally, in some further 
calculations, an SES-CD score of 0 represented a normal finding. The terms ―mucosal 
healing‖ in Study I and ―endoscopic remission‖ in Studies II, III, and IV are 
interchangable, even though their definitions vary somewhat. The term ―endoscopically 
inactive disease‖ in the results section for Studies I and II covers both of those terms. 
In Study III, the Mayo endoscopic subscore served for assessment of inflammatory 
activity in 26 UC patients. Endoscopic findings were graded as normal (0), mild (1), 
moderate (2), or severe (3); a subscore of 0–1 we defined as remission and a subscore of 
≥2 as active disease (D'Haens et al. 2007). 
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3.2 Faecal calprotecin and blood tests 
Faecal calprotectin was measured by a quantitative enzyme immunoassay (PhiCal Test; 
Calpro AS, Oslo, Norway), with <100 μg/g of stool considered normal (von Roon et al. 
2007). Blood count, serum albumin, and CRP were all determined routinely. 
 
3.3 Clinical activity scores 
The CDAI served as a measure for clinical disease activity as follows: <150 as clinically 
inactive disease; 150–219, mildly active disease; 220–449, moderately active disease; 
≥450, severe disease (Best et al. 1976, 1979, Sandborn et al. 2002). Despite a good 
correlation between CDAI and HBI, conversion of generally approved CDAI cut-off 
values to the less robust HBI is inexact. As no consensus exists on cut-off values for the 
HBI, its definitions for clinical remission differed between Studies III and IV: in III, 
HBI<4 indicated clinically inactive disease, HBI 4–7 mildly active disease, HBI 8–16 
moderately active disease, and HBI >16 severely active disease; whereas in IV, clinical 
remission was defined as HBI≤4 (Harvey and Bradshaw 1980, Best 2006, Vermeire et al. 
2010).  
The 26 UC patients in Study III were clinically assessed with the Mayo clinical subscore 
(total Mayo score without endoscopy). This subscore grades three clinical variables: 
frequency of defecation (0–3), amount of blood in stool (0–3), and overall well-being (0–
3). Clinical remission was defined as Mayo clinical subscore 0; mildly active disease as 1–
3; moderately active disease as 4–6; and severely active disease as ≥7 (D'Haens et al. 
2007). 
 
3.4 Statistics 
Continuous variables, expressed as medians and ranges or interquartile ranges (IQR), or 
as means and standard deviations, were compared by Student’s t-test. Correlations 
between variables were estimated with the two-tailed Spearman’s rank order correlation 
coefficient (r). Receiver operator characteristic (ROC) curves were created to analyze the 
accuracy of surrogate markers and clinical indices to identify endoscopic remission, and 
accuracy of SES-CD, CDAI, and calprotectin to predict it. The optimized cut-off level 
offered the best combination of sensitivity and specificity. Areas under the ROC curves 
were compared by Delong’s method. For Study III, a power calculation was performed. 
Statistical significance was set at p<0.05. Data were analysed by either NCSS 2004-
statistical software (NCSS Statistical Systems, Kaysville, UT, USA) (I), or IBM SPSS 
Statistics 17–19 software (IBM Corporation, Chicago, IL) (II-IV). 
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3.5 Ethics 
For participation in the studies, all patients gave their informed written consent. The 
ethics committee of the Helsinki University Central Hospital approved all studies. 
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RESULTS 
1 Predicting long-term endoscopic response 
1.1 Endoscopic assessment as a predictor for long-term treatment 
response 
Except for the retrospective nature of Study I and the prospective nature of Study II, 
these studies had similar structures and objectives. At baseline, all 71 patients in Study I 
presented with endoscopically determined moderate to very severe luminal inflammation 
(mucosal activity score 4–6) (Table 13). They were divided into two subgroups by 
indication for infliximab treatment: one subgroup of 51 patients with isolated luminal 
inflammation and another of 20 patients with luminal inflammation complicated by 
strictures or fistulae (complicated CD). A clearly higher frequency of smoking in the 
complicated CD subgroup was the only statistically significant difference in baseline data 
between subgroups. 
 
 
Table 13. Baseline data for patients in Study I and II 
 
 Study I 
n=71 
Study II 
n=42 
Sex, male/female, n (%) 36/35    (51/49) 22/20   (52/48) 
Age, years, median (range) 32.1   (16.8–73.3) 39.8   (19.1–66.7) 
Age at diagnosis, years, median (range) 22   (7–51) 24.5    (14–56) 
Duration of disease, years, median (range) 7   (0–30) 11    (1–45) 
Age at diagnosis according to Montreal classification, n (%)   
 <17 years 12   (17) 7    (17) 
 17–40 years 54   (76) 28    (67) 
 >40 years 5   (7) 7    (17) 
Localisation of disease, n (%)   
 Ileum 13   (18) 6    (14) 
 Colon 25   (35) 12    (28) 
 Ileum and colon 33   (46) 24    (57) 
Behaviour of disease, n (%)   
 Non-stricturing, non-penetrating 51   (72) 14    (33) 
 Stricturing 10   (14) 11    (26) 
 Penetrating 10   (14) 17    (40) 
 Perianal 13   (18) 9    (21) 
Current smoking, n (%) 25   (35) 18    (43) 
History of anti-TNF therapy, n (%) - 9    (21) 
Laboratory values   
 C-reactive protein, mg/l, median (range) 11   (<3–184) 9   (<3–105) 
 Haemoglobin, g/l, median (range) 128   (93–164) 124    (91–169) 
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Infliximab treatment usually commenced within one month after baseline endoscopy 
(median 0.6 months, range 0.0–5.5). At the first follow-up endoscopy at 3 months, 
patients had received 2 (range 1–3) infliximab infusions. At this point, of the 71 patients, 
53 (75%) displayed significant improvement in inflammatory activity as determined by 
endoscopy, and 32 (45%) had achieved mucosal healing (mucosal activity score 0–2). 
After the first follow-up endoscopy, further follow-up data were available on 57 patients. 
Of these 57, 44 (77%) continued infliximab for a period of 2.0 to 15.2 months, receiving 
a median of 3 infusions (range 1–8). At the second follow-up endoscopy performed at 
roughly one year after start of infliximab therapy, 34 (60%) had a positive endoscopic 
response and 30 (53%) presented with mucosal healing.  
 
Study II included 42 patients with endoscopically determined active luminal CD, all 
treated with anti-TNF (either adalimumab or infliximab) (Table 13). All underwent 
baseline endoscopy before start of anti-TNF. The findings of the 3-month follow-up 
endoscopy, performed 2.9 months (range 2.2–4.5) from start of anti-TNF, differed 
significantly from baseline endoscopic findings (baseline SES-CD 14.5, range 4–36, 3-
month SES-CD 5.5, range 0–24, p<0.001). All 10 patients in 3-month endoscopic 
remission and of the 32 patients with endoscopically active disease, 23 (72%) continued 
anti-TNF as maintenance therapy until the one-year follow-up or until they underwent 
bowel surgery. At the one-year follow-up, of those 33 receiving anti-TNF maintenance 
therapy, 11 (33%) were in endoscopic remission; additional deep remission, including 
both endoscopic and clinical remission, was present in 10 patients (30%).  
 
Although one-year endoscopically inactive disease was apparent in patients presenting 
either with endoscopically inactive or with active disease at the 3-month follow-up, after 
anti-TNF maintenance therapy, one-year endoscopically inactive disease was significantly 
more common in those who had presented with inactive disease at three months than in 
those who had presented with endoscopically active disease (Study I: 90% vs. 33%, 
p=0.0001; Study II: 70% vs. 17%, p=0.01) (Figures 1 and 2). 
 
Additionally, no patient with endoscopically inactive disease at 3 months developed 
complications requiring surgery during the follow-up. Four patients in Study I and six in 
Study II, each lacking any initial endoscopic response, underwent bowel surgery within 
12 months from the start of anti-TNF treatment because of complications arising from 
persisting disease activity. 
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Figure 1. 12-month endoscopic data according to 3-month mucosal healing or endoscopic remission 
of those 32 patients in Study I continuing infliximab and those 10 patients in Study II continuing either 
adalimumab or infliximab after 3 months. The mucosal activity score of 0–2 used in Study I implied no 
inflammatory activity or only very mild inflammation without ulcerations visible in endoscopy. SES-CD: 
simple endoscopic score for Crohn’s disease. Data adapted from figures from Studies I and II. 
 
 
 
  
 52 
 
 
 
 
 
Figure 2. Endoscopic remission, endoscopically active disease, and surgeries at 12 months according 
to 3-month endoscopy indicating active disease in those 24 patients in Study I who continued infliximab 
and in those 23 patients in Study II who continued either adalimumab or infliximab after 3 months. The 
mucosal activity score of 0–2 used in Study I implied no inflammatory activity or only very mild 
inflammation without ulcerations visible in endoscopy. SES-CD: simple endoscopic score for Crohn’s 
disease. Data adapted from figures from Studies I and II. 
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No infections or other adverse effects necessitating discontinuation of anti-TNF therapy 
nor any deaths occurred during follow-up. In terms of endoscopically determined 
disease activity, patients in Study I with isolated luminal inflammation appeared to 
respond better to infliximab therapy than did patients with complicated disease. A 
positive endoscopic response at the first follow-up was significantly more common in 
the pure luminal inflammation group than in the complicated CD group (84% vs. 45%, 
p=0.003 at 3 months and 69% vs. 33%, p=0.02 at 12 months). Significant differences in 
mucosal healing, however, emerged between the two subgroups only at 12 months (64% 
vs. 20%, p=0.003). Neither localisation, duration of disease, age at diagnosis, current age, 
number of infliximab infusions, nor use of concomitant immunosuppressive medication 
showed any association with the positive or negative endoscopically determined 
response, nor with mucosal healing.  
 
In Study II, at baseline neither patient nor disease characteristics predicted long-term 
endoscopic outcome: in a logistic regression analysis of patients in Study II, the 3-month 
SES-CD proved the only predictor for one-year endoscopic remission with statistical 
significance (p=0.03, odds ratio 0.793, 95% confidence interval 0.644–0.978). A ROC 
curve analysis for the 3-month SES-CD (using its cut-off value of <3) revealed a 90% 
sensitivity and 64% specificity to predict one-year endoscopic remission in patients 
receiving anti-TNF maintenance therapy (Figure 3). 
Figure 3. Receiver under the operating characteristic (ROC) curves depicting the SES-CD (AUC 
0.793±0.160, p=0.004) and CDAI (AUC 0.620±0.196, p=0.25) at 3 months from start of anti-TNF as 
prognostic tests for endoscopic remission, defined as SES-CD≤2, at 12 months, n=42. 
SES-CD: Simple endoscopic score for Crohn’s disease; CDAI: Crohn’s disease activity index; anti-TNF: 
anti-tumour necrosis factor-α antibody; AUC: Area under the ROC curve; sens: sensitivity; spec: 
specificity. Data adapted from a figure from Study II. 
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1.2 Non-invasive disease-activity assessment as a predictor for long-
term treatment response 
At baseline, all 60 IBD patients in Study III had elevated faecal calprotectin levels (mean 
810 μg/g, range 103–12,258 μg/g). After induction with anti-TNF, their calprotectin 
levels had fallen to a mean 97 μg/g (range 0–5,859 μg/g, p<0.001), and in 31 patients 
calprotectin had normalized. Of these 31 patients with normal postinduction 
calprotectin, 27 had a calprotectin decline of more than 75% from baseline. Based on 
calprotectin levels after anti-TNF induction, the patients were divided into two groups: a 
normal-postinduction calprotectin group and an elevated-postinduction calprotectin 
group. Those with the latter who were in clinical remission had a significantly lower 
calprotectin (median 204 μg/g, range 116–670 μg/g) than did those with clinically active 
disease (median 496 μg/g, range 123–2,896 μg/g, p=0.025). At one year, of the original 
60 patients, 37 (62%, 27 CD and 10 UC) were in clinical remission, 15 (25%, all UC) had 
undergone surgery, and 8 (13%, 7 CD and 1 UC) had clinically active disease. Of those 
31 patients with a normal postinduction calprotectin, 26 (84%) were in clinical remission, 
whereas a significantly smaller proportion of the patients with an elevated postinduction 
calprotectin had achieved clinical remission (11 patients, 38%, p=0.0002) (Figure 4).  
 
 
Figure 4. One-year clinical remission in inflammatory bowel disease patients, defined as Harvey-
Bradshaw index<4 or Mayo clinical subscore=0, according to postinduction calprotectin levels (Study 
III). Faecal calprotectin<100 μg/g: normal; ≥100 μg/g: elevated. Normal postinduction calprotectin 
group: 26 patients of 31 in clinical remission at one year; elevated postinduction calprotectin group: 11 
patients of 29 in clinical remission at one year.  
 
  
26/31 11/29 
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Of those 27 patients with more than a 75% calprotectin decline at postinduction 
assessment, 22 (82%) were in clinical remission at one year. At one year, of those 48 
patients on maintenance therapy, 25 had available calprotectin concentrations. In these 
patients, of 17 with a normal postinduction calprotectin, 13 (76%) still showed normal 
calprotectin, whereas of 8 with an elevated postinduction calprotectin, 4 (50%) showed 
normal one-year calprotectin. At one year, 38 patients (27 CD and 11 UC) underwent 
endoscopic reassessment.  Endoscopic remission at one year was also more common, 
although not statistically significant, in those with normal postinduction calprotectin 
compared to those with elevated postinduction calprotectin (17 of 23, 74% vs. 7 of 15, 
47%, p=0.089).  
 
With ROC statistics we analysed the power of postinduction calprotectin levels to 
predict long-term clinical outcome. Calprotectin with a cut-off 139 μg/g showed a 
sensitivity of 72%, a specificity of 80%, and an area under the ROC curve (AUC) of 
0.838 to predict one-year clinical relapse. Because of the small subgroups, no separate 
cut-offs for CD and UC patients were reasonable to calculate. Additional calculations 
allowed analysis of the predictive power of calprotectin decline from baseline to 
postinduction assessment. An 88% calprotectin decline during anti-TNF induction 
predicted clinical remission at one year with a sensitivity of 87% and specificity of 65% 
and with an AUC of 0.771. 
In Study II, clinical and laboratory data enabled assessment of one-year endoscopic or 
surgical outcome, based on clinical symptoms and CRP after 3 months of anti-TNF 
therapy. Neither CRP nor the CDAI (Figure 3) at 3 months showed any connection 
with 12-month endoscopic remission. 
 
 
2 Non-invasive markers of disease activity as replacement for 
endoscopy 
Of a total of 210 endoscopic assessments at baseline prior to, and 3, 12, 24, and 36 
months after start of anti-TNF in the 64 patients in Study IV, no inflammatory lesions at 
all (SES-CD=0) were detectable in 29 endoscopies (14%), and endoscopy indicated 
remission (SES-CD≤2) in 42 assessments (20%). The proportion of assessments 
indicating clinical remission according to the CDAI (98 of 141, 69%) and the HBI (100 
of 150, 67%) was almost three times as high, and CRP was normal (103 of 209, 49%) 
nearly twice as often as SES-CD-indicated remission. The proportion of disease activity 
assessments with a normal calprotectin (37 of 126, 29%) was, on the other hand, nearly 
identical to the proportion for SES-CD-indicated remission. However, of those 37 
disease-activity assessments with normal calprotectin, concurrent active disease was 
visible in 16 endoscopies (11 with mild, 3 with moderate, and 2 with severe 
inflammation according to the SES-CD). 
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Although the endoscopic score showed a correlation with clinical indices and surrogate 
markers, the SES-CD showed a weaker correlation with both the CDAI (r=0.40, 
p<0.001) and HBI (r=0.32, p<0.001) than the concurrent correlations of SES-CD with 
CRP (r=0.56, p<0.001) and calprotectin (r=0.56, p<0.001). The strongest correlations 
were between the CDAI and the HBI (r=0.73, p<0.001). When categorizing disease 
activity according to the clinical indices into clinical remission, and clinically mild, 
moderate, and severe disease, statistically significant differences in both the SES-CD and 
CRP were more difficult to detect. For example, SES-CD scores in the CDAI remission 
group did not differ from those scores in the CDAI mild-activity group. A 
corresponding categorization for the SES-CD grouped assessments into endoscopic 
remission, endoscopically mild, moderate, and severe disease. Although statistically 
significant differences emerged between a majority of the groups in both clinical indices 
and surrogate laboratory markers, only calprotectin was capable of detecting significant 
differences between SES-CD remission- and mild- and moderate-activity groups. CRP in 
turn managed to detect a significant difference between the SES-CD moderate- and 
severe-activity groups, but on the other hand it failed to distinguish between SES-CD 
remission and mild activity.  
 
We carried out ROC curve calculations to analyse the power of clinical indices and 
surrogate markers to detect endoscopic remission. With the SES-CD cut-off value 2 for 
differentiating endoscopic remission from active disease, the AUC for calprotectin was 
0.854. With a calprotectin cut-off value set at the commonly used 100 μg/g, sensitivity 
was 81% and specificity 74%. The level of 94 μg/g was optimized as the best 
calprotectin cut-off value, with a slightly higher sensitivity of 84% and a specificity of 
74% in detecting endoscopic remission. However, the positive predictive value for 
calprotectin remained low, at 50%, whereas its negative predictive value was 97%. In our 
search for a normal endoscopic finding, using the SES-CD cut-off value 0, the sensitivity 
and specificity for calprotectin were quite similar, 82% and 78%, with the optimized 
calprotectin cut-off value 94 μg/g. CRP, CDAI, and HBI were poor at detecting 
analogous endoscopic remission (Table 14 and Figures 5 and 6). 
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Table 14. Performance data for clinical indices, faecal calprotectin, CRP, and combined 
scores for identifying endoscopic remission. 
 
Cut-off 
 
Sensi-
tivity 
% 
Speci-
ficity 
% 
AUC 
 
PPV 
% 
NPV 
% 
CDAI, n=141 55 71 64 0.730 40 91 
HBI, n=150 1 80 56 0.729 38 94 
Faecal calprotectin (μg/g), n=126 94 84 74 0.854 50 97 
CRP (mg/l), n=209 3 50 24 0.643 24 86 
HBI + 2 × ln[Calprotectin (μg/g)],  n=106 10 85 82 0.900 57 93 
Calprotectin (μg/g) + 60 × HBI, n=106 155 86 82 0.880 60 95 
CRP (mg/l) + 3 × HBI, n=150 4 80 59 0.766 47 87 
AUC: area under the ROC (receiver-operating characteristic) curve; PPV: positive predictive value; NPV: negative 
predictive value; CDAI: Crohns disease activity index; HBI: Harvey-Bradshaw index; CRP: C-reactive protein; ln: 
natural logarithm. All cut-offs are optimized. Data from Study IV. 
 
 
 
 
Figure 5. Receiver under the operating characteristic (ROC) curves depicting utility of the CDAI and 
the HBI as detectors of endoscopic remission, defined as SES-CD 0–2. CDAI: Crohn’s disease activity 
index; HBI: Harvey–Bradshaw index; SES-CD: Simple endoscopic score for Crohn’s disease; AUC: Area 
under the ROC curve.  
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Discrepancies in proportions of patients in endoscopic remission and in clinical 
remission were also evident in Study II. According to the CDAI, of the 42 patients, 14 
(33%) were in clinical remission at the start of anti-TNF, despite their endoscopically 
active disease; at both follow-ups, a substantially greater proportion were in clinical 
remission compared with those in endoscopic remission (76% and 73% vs. 24% and 
33%).  At baseline and at both follow-ups, normal CRP was also clearly more frequent 
than was endoscopic remission, whereas proportions of patients with normal 
calprotectin were more similar to proportions with endoscopically determined remission. 
However, at baseline calprotectin was normal in two patients (73 and 93 μg/g) despite 
their moderate or severe inflammation (SES-CD 11 and 18) according to endoscopy.  
 
 
3 A non-invasive combination score for detecting endoscopic 
remission 
In Study IV, of 210 disease activity assessments, 126 had available concomitant data on 
faecal calprotectin and on the SES-CD. Because of the low positive predictive value of a 
normal calprotectin level (<100 μg/g), we analysed further the possibility of improving 
identification of endoscopic remission by combining existing noninvasive methods. We 
created ROC curves based on the sums of differently emphasized and combined HBI, 
CDAI, calprotectin, and CRP and analysed their power to detect endoscopic remission. 
Scores based on the HBI and calprotectin (n=106) proved superior—although without 
statistical significance—to other combinations and to calprotectin alone. The highest 
AUC, 0.900, was for the following score: HBI + 2 × ln[Calprotectin (μg/g)]. With its 
sum 10 as the cut-off value for endoscopic remission, its sensitivity was 85%, specificity 
82%, positive predictive value 57%, and negative predictive value 93%. We also 
developed a simplified non-logarithmic score in which the AUC still remained slightly 
higher than with calprotectin alone (AUC 0.880): Calprotectin (μg/g) + 60 × HBI 
(Figure 6). 
 
In further calculations, defining endoscopic remission as SES-CD≤3 only marginally 
impaired the remission-detecting power of the markers and indices, without changing 
the superiority of calprotectin and a calprotectin-HBI combination over CRP and the 
clinical indices. In the search for endoscopies limited to no detectable inflammatory 
lesions (SES-CD=0), the original combined score HBI + 2 × ln[Calprotectin (μg/g)] still 
proved superior to that of calprotectin alone; it had an AUC of 0.905, with sensitivity 
84% and specificity 83%. Although the clinical indices and CRP, used alone or in 
combination, proved inferior to calprotectin alone, the score CRP + 3 × HBI seemed to 
improve identification of endoscopic remission, compared with results of either test 
separately (Figure 6). Performance data for the combined scores are included in Table 
14. 
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Figure 6. Receiver under the operating characteristic (ROC) curves that demonstrate the power of 
scores, combining a) faecal calprotectin and the HBI and b) CRP and the HBI, as detectors of 
endoscopic remission, defined as SES-CD 0–2. Faecal calprotectin and plasma CRP are depicted with 
dotted lines for comparison. No differences with statistical significance. HBI: Harvey–Bradshaw index; 
CRP: C-reactive protein; SES-CD: Simple endoscopic score for Crohn’s disease; AUC: Area under the 
ROC curve. 
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DISCUSSION 
1 Endoscopy as a predictor of long-term endoscopic outcome 
The present results, both retrospective and prospective, indicate that endoscopic 
findings at three months after the start of anti-TNF in patients with luminally active CD 
are highly predictive for one-year endoscopic response rate. Endoscopic remission 
achieved at three months is associated with a significantly higher probability of sustained 
endoscopic remission during maintenance therapy at one year (90% in Study I and 70% 
in Study II), compared with remission probability if the three-month endoscopic finding 
demonstrates active mucosal inflammation (33% in Study I and 17% in Study II). The 
impact of early endoscopic findings on one-year endoscopic response was very similar to 
that of Hébuterne and coworkers (2013) in the MUSIC study. Use of certolizumab pegol 
in their study appears the most important difference, though their different endoscopic 
indices are of marginal relevance due to their strong correlations and their similar 
definitions for remission.  
Early mucosal healing as a predictor of long-term mucosal healing was not, however, as 
evident in the EXTEND trial. In that prospective, placebo-controlled, double-blind 
study of CD patients treated with adalimumab, mucosal healing was the primary end-
point. Of 17 patients with mucosal healing at week 12 who received continuous 
adalimumab, only 8 (47%) had maintained it at week 52 (Rutgeerts et al. 2012). This 
difference may be explained by strict study inclusion criteria comprising a CDAI score of 
more than 220 points and mucosal ulcers seen at screening endoscopy, and in addition 
explained by exclusion from primary analysis if patients were switched to open-label 
adalimumab therapy during follow-up.  
 
Since the beginning of anti-TNF therapy, mucosal healing has become an important 
predictor of long-term disease outcome in IBD. Mucosal healing during scheduled 
infliximab therapy reduces need for surgery and hospital treatment significantly 
(Schnitzler et al. 2009). Recently, one study demonstrated that in patients with early-stage 
CD, complete mucosal healing can lead to significantly higher steroid-free remission 
rates even for four years after start of therapy (Baert et al. 2010). Increasing focus on the 
concept of therapy quality has also contributed to evolution of treatment goals from 
endoscopic healing towards deep remission, a combination of clinical and endoscopic 
remission (Hommes et al. 2012, Rutgeerts et al. 2012, Travis et al. 2012). The EXTEND 
study sub-analysis demonstrated that all patients who achieved deep remission at week 
12 avoided hospitalization during that one-year study. Deep remission was also 
associated with higher quality of life and lower health-care costs (Colombel et al. 2011).  
Our group, on the other hand, were able to show that endoscopic remission achieved at 
three months from start of anti-TNF was associated with deep remission at one year. 
However, as the definition of endoscopically determined mucosal healing is unsettled, 
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the concept of deep remission must evolve.  
Although both the CDEIS and the SES-CD have served in several treatment studies, 
their numerical cut-off values are insufficiently defined. The rougher CDEIS cut-off 
between 6 and 7 suggested by Mary and coworkers (2005) has later met criticism. 
Baseline median CDEIS was 8.8, and scheduled infliximab therapy resulted in a 93% 
change in the CDEIS at week 54 in an endoscopic substudy of ACCENT 1 (Rutgeerts et 
al. 2004). In another study exploring endoscopic response to infliximab, median CDEIS 
levels after 10 and 54 weeks of therapy were less than 3 (Geboes et al. 2005). The latter 
study considered CDEIS levels less than 5 as endoscopically mild disease, 5 to 15 as 
moderate, and above 15 as severe. A CDEIS cut-off between 6 and 7 appears too high, 
when we consider the definition of mucosal healing as being the complete absence of 
ulcers, because in only one single bowel segment, one single deep ulcer involving 50% of 
the surface, plus disease covering 50% without stenosis all results in a CDEIS sum of 4.4 
([12+5+5]/5).  
Neither the CDEIS nor the SES-CD has been adopted for larger prospective clinical 
trials. Trials such as ACCENT-1, EXTEND, and SONIC have used the definition 
―absence of ulcers‖ as their main endoscopic endpoint (Hanauer et al. 2002, Colombel et 
al. 2010, Rutgeerts et al. 2012). This definition is tempting and is probably convenient in 
a study setting, but it is unimaginable that such a strict ―black-and-white‖ endpoint could 
represent the only relevant treatment goal in clinical practice. The impact of significant 
endoscopic improvement is also unsettled, although post-hoc analysis of the SONIC 
endoscopic data has suggested that a reduction in ulcer load by half may be as clinically 
relevant as the complete disappearance of ulcers (Ferrante et al. 2011). Studies on 
validating cut-offs for the SES-CD are limited (Moskovitz et al. 2007). Nonetheless, as 
significant correlations exist between these indices, and as endoscopic remission defined 
as SES-CD<3 corresponds to the CDEIS<3 definition (Sipponen et al. 2010a), use of 
the more simple SES-CD seems justified both in clinical practice and in the present 
study.  
 
This study has its limitations. In a purely observational design, our endoscopic and 
surgical end-points and laboratory and clinical findings present the outcome of a 
heterogeneous CD patient group during treatment with anti-TNF in real-life clinical 
practice. Confounding relevant factors are our use of both adalimumab and infliximab 
and their varying dosages and the small proportion of UC patients in Study III. The 
differing proportions of patients with endoscopically inactive disease at three months 
between Study I (45%) and Study II (24%) may at least in part be explained by lack of 
any validated endoscopic scoring method in Study I. Scoring according to mucosal 
activity in the most affected bowel segment is likely to produce lower values than values 
with the SES-CD, whose total score is calculated from sums of variables recorded from 
up to five bowel segments. Further, no validation of the SES-CD in a postoperative 
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setting exists, but studies using the SES-CD in similar proportions of patients with a 
history of surgery are published (Sipponen et al. 2010a, b).  
Our lack of control groups and our study’s observational nature hampered estimation of 
the real endoscopic impact of anti-TNF therapy, although evidence that anti-TNF 
maintenance therapy in CD induces mucosal healing significantly more often than does 
placebo is strong (D'Haens et al. 1999b, Rutgeerts et al. 2006, 2009). In one small-scale 
endoscopic study of 22 patients in a placebo-controlled infliximab trial, no endoscopic 
improvement appeared in the placebo group. Mucosal healing, defined as complete 
absence of mucosal ulcerations, was documented for almost half at the first follow-up 
endoscopy. When infliximab was continued with scheduled therapy in patients with an 
objective initial positive response, mucosal healing was observable in nearly all patients. 
However, due to the limited number assessed by colonoscopy, no reliable analysis was 
possible of factors predictive for response (D'Haens et al. 1999b). In the ACCENT I 
endoscopic substudy, with its 99 patients, mucosal healing occurred in 18% with 
episodic therapy, increasing to 42% in patients on 5 mg/kg dosage, and to 47% on 10 
mg/kg scheduled therapy (Rutgeerts et al. 2006, 2009). The decision to continue 
infliximab therapy in the ACCENT I trial was, however, based on clinical responses 
according to the CDAI (Hanauer et al. 2002).  
 
 
2 Surrogate markers as replacement for endoscopy and in 
predicting long-term outcome 
The emerging need for surrogate markers of mucosal inflammatory activity rises from 
the numerous drawbacks of endoscopic procedures. Based on our results, we can 
cautiously claim that in current clinical practice, in active CD, only calprotectin (or 
another corresponding faecal marker) may be a useful non-invasive surrogate marker for 
endoscopic assessment of luminal inflammatory activity. It is also useful for 
distinguishing endoscopically active disease from endoscopic remission. Whereas 
elevated faecal calprotectin levels are indeed highly predictive of active mucosal 
inflammation, the utility of low faecal calprotectin levels in predicting inactive disease is 
still, however, inconclusive (Langhorst et al. 2008, Sipponen et al. 2008b, Schoepfer et al. 
2010, D'Haens et al. 2012).  
 
Compared to faecal markers, other methods to assess mucosal inflammatory activity in 
clinical practice appear to be clearly inferior. The CDAI reportedly underestimates 
endoscopically determined inflammatory activity; therefore, remission determined solely 
by clinical indices cannot be considered complete (Sipponen et al. 2008c). Our study 
results are similar: differences in endoscopic and established clinical remission rates 
during anti-TNF therapy in active luminal CD were considerable. If efficacy of therapy 
means the achievement of endoscopic remission, then our results from anti-TNF 
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treatment were clearly poorer than if we had defined efficacy as clinical remission. The 
power of CRP, due to its poor specificity, to recognize endoscopic remission is also far 
below that of calprotectin. Hence, a normal CDAI or CRP is inefficient in recognizing 
mucosal healing. However, when comparing inflammation markers, one should also bear 
in mind that the fistulae and strictures in a considerable proportion of CD patients may 
have a more pronounced effect on CRP and clinical indices than on calprotectin. 
 
Roseth and coworkers (2004) demonstrated that mucosal healing could be determined 
by the calprotectin in a simple stool sample. In that study, histological examination of 45 
patients with a normal calprotectin showed normal findings for 38; the rest had 
histologically determined mild inflammation. In a study of 77 CD patients who 
underwent 106 endoscopic and concurrent stool-marker assessments, Sipponen and 
coworkers (2008c) demonstrated a significant correlation between faecal calprotectin and 
the CDEIS (r=0.729, p<0.001). The CDEIS definition for remission was set at 0 to 2, 
allowing for only some minor lesions. For use in clinical practice, they suggested 
calprotectin values <200 μg/g for endoscopically inactive disease (sensitivity 70%, 
specificity 92%) and values >1000 μg/g for markedly active disease (sensitivity 69%, 
specificity 93%).  
The power of calprotectin to distinguish between mucosal healing and endoscopically 
active disease is also a topic of Schoepfer and coworkers (2010), who in a study of 122 
CD patients tested the hypothesis that calprotectin outmatches other noninvasive tests at 
making distinctions among patient groups based on severity of endoscopic disease 
activity. In defining active luminal inflammation as SES-CD≥4, sensitivity for 
calprotectin was 89% and specificity 72% with a calprotectin cut-off >70 μg/g, 
outscoring the CRP sensitivity of 68% and specificity of 58%. In a more recent 
calprotectin study of IBD and IBS by D'Haens and coworkers (2012), calprotectin levels 
≤250 µg/g identified endoscopic remission in CD, defined as CDEIS≤3, with a 
sensitivity of 94% and a specificity of 62%. Lobatón and coworkers (2013), who recently 
analysed stool markers obtained in connection with 115 endoscopies, defined 
endoscopic remission as a CDEIS<3. They suggested a calprotectin cut-off as high as 
274 µg/g. A calprotectin level of >250 µg/g can easily be interpreted as abnormal, 
whereas the calprotectin endoscopic remission cut-offs reported by D'Inca (2007), 
Langhorst (2008), and Schoepfer (2010) and coworkers, and the cut-off 94 µg/g in our 
studies all fall within the usual normal.  
 
Apart from endoscopy, clinically relevant factors predicting long-term mucosal healing 
are insufficiently clarified. The results of retrospective Study III indicate that a normal 
calprotectin after induction with anti-TNF is capable of predicting clinical and possibly 
also endoscopic remission after twelve months of maintenance therapy with anti-TNF in 
both CD and UC. In comparison to the SES-CD obtained at the same point, by ROC 
statistics applied to our prospective patient material, calprotectin turned out to be even 
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more sensitive and specific in predicting twelve-month endoscopic remission. Because 
of our small number of patients with available data, no statistically significant differences 
were, however, detectable. Furthermore, our studies reveal the inferiority of the CDAI 
and of CRP as predictive markers of long-term mucosal healing, compared with results 
of the SES-CD. The low CRP at week 12 and clinical remission at week 24 as predictive 
factors for one-year mucosal healing suggested by Kiss and coworkers (2012) await 
verification. Their very strict definition for mucosal healing (completely normal 
endoscopic findings), makes any direct comparison with our results quite difficult. 
Furthermore, calprotectin appears useful as a predictor of clinical relapse. Calprotectin 
levels reportedly differ significantly between relapsing and non-relapsing IBD patients 
(Tibble et al. 2000b). Calprotectin may also be a stronger clinical relapse predictor in UC 
than in CD (Costa et al. 2005). On the other hand, a more recent study demonstrates that 
calprotectin levels >130 µg/g can predict clinical relapse in both UC and colonic CD 
(D'Inca et al. 2008). Comparable findings appear in a study reporting a six-fold increase 
in relapse within one year in UC cases with baseline calprotectin over 120 µg/g, and a 
four-fold increase in CD if the baseline calprotectin level is over 200 µg/g (Garcia-
Sanchez et al. 2010). To the best of our knowledge, no published articles demonstrate the 
usefulness of faecal calprotectin in estimating CD outcome after induction with anti-
TNF. One study, published only as an abstract, reported that normalization of 
calprotectin correlated significantly with clinical response after anti-TNF induction 
(Guidi et al. 2010). In that study, faecal calprotectin more than 150 µg/g after induction 
therapy indicated increased risk for clinical relapse at one year. This is in line with our 
results, where a calprotectin cut-off concentration of 139 µg/g was capable of 
distinguishing between a high and a low relapse risk during anti-TNF maintenance 
therapy. Additionally, our results indicate that one-year outcomes are almost equal 
between patients with normalized postinduction calprotectin and patients with a 
considerable postinduction calprotectin decline. The best predictive value for decline in 
calprotectin in our analysis was 88%. It is therefore reasonable to consider patients with 
a calprotectin decline of more than 88% as responders, along with those with normal 
calprotectin levels.  
The consequence of our having heterogeneous patients, our differing endoscopic indices 
and their varying cut-offs for defining endoscopic remission, makes the determination of 
exact cut-offs for faecal markers in clinical practice a real challenge. In current clinical 
practice, the use of uniform calprotectin reference values set by the manufacturer may be 
misleading. Defining a normal or an acceptable calprotectin level for any individual 
should require knowledge of his or her patient category. The calprotectin cut-off should 
probably be higher in patients with known inflammatory bowel disease, and lower for 
merely screening purposes. Cut-offs also possibly need further individual adjustment 
based on patient history. 
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3 Identifying endoscopic remission by combining non-invasive 
markers and clinical indices  
A simple combined clinical score, based on calprotectin and the HBI, appeared to be 
even more specific and sensitive, with better predictive success in identifying endoscopic 
remission than was calprotectin alone. In clinical practice, this combined score could 
likely ease the identification of patients in endoscopic remission, as all data required are 
easily obtained by a simple laboratory test and a brief patient interview. One of the few 
studies of such noninvasive combined activity indices involved 43 patients with CD; 
Langhorst and coworkers (2008) here developed a comprehensive activity index for 
discriminating endoscopically active inflammation from inactive inflammation. This 
index, comprising the CDAI, CRP, and three stool markers, had a sensitivity of 79% and 
a specificity of 70%, superior to both CRP and the CDAI, but still inferior to 
calprotectin alone. Direct comparison of this comprehensive index with our combined 
score is not feasible, due to several differences: their comprehensive index was based on 
dichotomous variables, its endoscopic scoring was not based on an endoscopic score, 
and its cut-off values for both the CDAI (>80) and the laboratory markers (calprotectin 
>48 μg/ml, CRP >7mg/l) differed.  
The combined score, however, reveals a paradox. Several studies have demonstrated that 
in IBD patients with bowel symptoms, a normal calprotectin level is helpful in 
distinguishing IBD from IBS and ruling out active disease (Tibble et al. 2000a, D'Inca et 
al. 2007, Kaiser et al. 2007, Langhorst et al. 2008). This finding is already well 
implemented in clinical practice. Yet the present study identified CD patients with 
apparently normal calprotectin levels but with active bowel inflammation revealed by 
endoscopy. In several of these patients, the combined score indicated active disease 
because of the rise in HBI score derived from subjective symptoms. This phenomenon 
may be explained by natural fluctuation in daily calprotectin levels and the fact that such 
a ―normal‖ calprotectin based on laboratory reference values may, in a subgroup of CD 
patients, still be abnormal. This is a reminder of the importance of observing CD as a 
whole, not overlooking subjective symptoms in patients with objectively, but only non-
invasively, suggested quiescent disease.  
The new combined score was developed in patients originally receiving anti-TNF. 
Because many disease-activity assessments occurred during no anti-TNF exposure at all, 
its use should be unquestionable in patients with luminal CD independent of type of 
therapy. With the combined score’s failure to reach statistical superiority to that of 
calprotectin alone, recognition of endoscopically active disease in those patients with 
normal calprotectin and mild subjective symptoms remains a challenge. The value of the 
combined score, as demonstrated here, must be confirmed in prospective series; further 
research into other combined scores is essential. A valid combined score would be an 
important, simple, and cost-effective tool in CD treatment, to direct endoscopy 
resources to those patients with active disease.  
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CONCLUSION 
Today, when medical treatment of CD increasingly is based on efficient but expensive 
highly immunosuppressive anti-TNF, achievement of an objective treatment response 
and identification of reliable predictive markers would provide an optimal cost-benefit 
ratio. Although endoscopy remains the treatment of choice for objective assessment of 
mucosal inflammation, the need exists to replace endoscopy with noninvasive surrogate 
markers. Based on the present work, objective disease-activity assessment of mucosal 
healing, performed as early as three months after start of anti-TNF, appears to offer the 
best prognostic evaluation of treatment in luminal CD. Additionally, both a normal 
calprotectin and a considerable calprotectin drop from baseline are promising as 
predictive markers for long-term remission. By combining calprotectin, its elevation as a 
reliable marker for endoscopically active disease, and a clinical index such as the HBI, 
detection of endoscopic remission may improve. Adapted for clinical practice, these data 
would suggest routine assessment of faecal calprotectin at baseline and at the three-
month follow-up after initiation of anti-TNF, with low-threshold referral to endoscopy 
in suspected nonresponders within a year after initiation of therapy.   
The question of objective treatment response is still open, however, due to limited data 
on validated cut-off values for remission and response from endoscopic indices and 
faecal calprotectin. Even were mucosal healing regarded as the primary goal in treatment 
of CD, differentiating among other disease activity levels is also necessary in assessment 
of treatment response, particularly in those patients unable to achieve endoscopic 
remission.  
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FINNISH AND SWEDISH SUMMARIES 
Yhteenveto 
Tausta 
Crohnin tauti on krooninen, useimmiten paksusuolessa ja ohutsuolen loppuosassa 
esiintyvä suolitulehdus. Sen tyypillisiä oireita ovat vatsakivut, laihtuminen, veriset ulosteet 
ja ripuli, jotka pahimmillaan johtavat pysyvään työkyvyttömyyteen. Taudin vaikeampia 
ilmentymiä voidaan hoitaa tuumorinekroositekijä α:n vasta-aineilla (anti-TNF), jotka 
monessa tapauksessa ovat riskialttiita ja joista vain osa potilaista hyötyy. 
Tutkimusten mukaan paksusuolen tähystyksellä osoitettava limakalvon paraneminen 
ennustaa vahvasti suotuisaa pitkäaikaishoitovastetta. Hoitovasteen seuranta voi kuitenkin 
olla haastavaa, koska suolen limakalvon tulehdusaktiviteetti ei välttämättä korreloi 
potilaan subjektiivisten oireiden kanssa. 
Koska tähystys on aikaavievä, kallis ja monelle potilaalle kivulias tutkimus, on kehitetty 
kajoamattomia korvaavia menetelmiä tautiaktiviteetin arvioimiseksi. Korvaavien 
merkkiaineiden, kuten ulosteen kalprotektiinin, kyky tunnistaa tähystyksellä osoitettava 
limakalvoparaneminen, on riittämättömästi selvitelty. Limakalvoparanemista ennustavia 
tekijöitä anti-TNF-hoidon aikana on myös vajavaisesti tutkittu. 
Potilaat ja menetelmät 
Väitöskirjatyö koostui neljästä osatyöstä (I–IV). Pitkäaikaiseen limakalvoparanemiseen 
liittyvien tekijöiden löytämiseksi analysoitiin sekä takautuvasti (I: 71 potilasta, III: 60 
potilasta) että prospektiivisesti (II: 42 potilasta) kerättyä tietoa anti-TNF-hoidetuilta 
Crohnin tautia sairastavilta potilailta. Lisäksi selviteltiin mahdollisuuksia korvata 
paksusuolen tähystys kajoamattomilla merkkiaineilla ja kliinisillä oireindekseillä (IV: 
tiedot yhteensä 210 tähystystutkimuksesta). 
Tulokset 
Limakalvoparaneminen kolme kuukautta hoidon aloituksesta oli vahva ennustetekijä sen 
jatkumiselle vielä vuoden jälkeen. Myös normaali kalprotektiini noin kolmen kuukauden 
hoidon jälkeen ennusti suotuisaa vastetta vuoden jälkeen. Kalprotektiini oli paras 
yksittäinen merkkiaine tunnistamaan samanaikainen limakalvoparaneminen. Uusi, 
tutkimusryhmän kehittämä, kliinisestä oireindeksistä ja kalprotektiinista koostuva 
yhdistelmäindeksi osoittautui vielä kalprotektiinia herkemmäksi ja tarkemmaksi 
limakalvoparanemisen tunnistamisessa. 
Päätelmät 
Paksusuolen tähystys tai kalprotektiinin määritys kolme kuukautta hoidon aloituksesta 
optimoi anti-TNF-hoitoa Crohnin taudissa. Kliinistä oireindeksiä ja ulosteen 
kalprotektiinia yhdistelevän uuden indeksin avulla voidaan paremmin ohjata rajalliset 
tähystysresurssit sitä eniten tarvitseville potilaille. 
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Sammanfattning 
Bakgrund 
Crohns sjukdom är en kronisk tarminflammation som oftast drabbar tjocktarmen och 
slutet av tunntarmen. Vanliga symtom är buksmärta, viktminskning, blodig avföring och 
diarré, vilket i värsta fall leder till arbetsoförmåga. Sjukdomen kan behandlas med 
antikroppar mot tumörnekrosfaktor α (anti-TNF), en i många fall riskabel behandling 
som endast en del patienter drar nytta av.  
Forskning visar att en i koloskopi påvisbar läkning av tarmslemhinnan är starkt kopplad 
till en gynnsam prognos. Uppföljningen av behandlingsresponsen är dock utmanande, 
eftersom tarmslemhinnans inflammatoriska aktivitet inte nödvändigtvis korrelerar med 
patientens subjektiva symtom.  
Eftersom koloskopi är en tidskrävande, dyr och ibland smärtsam undersökning, har man 
utvecklat ersättande noninvasiva metoder för att uppskatta sjukdomsaktiviteten. 
Surrogatmarkörers, bland annat det fekala kalprotektinets, förmåga att upptäcka 
endoskopiskt påvisbar slemhinneläkning är dock otillräckligt utredd. Likaså är 
prognostiska faktorer för långvarig slemhinneläkning under anti-TNF-behandling 
bristfälligt klarlagda. 
Patienter och metoder 
Avhandlingsprojektet bestod av fyra delarbeten (I–IV). För att identifiera faktorer 
kopplade till långvarig slemhinneläkning analyserades både retrospektivt (I: 71 patienter, 
III: 60 patienter) och prospektivt (II: 42 patienter) insamlade uppföljningsdata från 
patienter med anti-TNF-behandlad Crohns sjukdom. Utöver detta utreddes möjligheter 
att ersätta koloskopi med surrogatmarkörer och kliniska symtomindex (IV: data från 
sammanlagt 210 endoskopiundersökningar). 
Resultat 
Slemhinneläkning tre månader efter att behandlingen börjat var en stark prognostisk 
markör för fortsatt slemhinneläkning vid ett år. Ett normalt fekalt kalprotektin efter cirka 
tre månaders behandling förutspådde också en gynnsam ettårsprognos. Fekalt 
kalprotektin var den bästa enskilda surrogatmarkören för att upptäcka slemhinneläkning 
vid samma tidpunkt. Ett nytt, av forskningsgruppen utvecklat kombinerat aktivitetsindex 
som består av ett kliniskt aktivitetsindex och kalprotektin, uppvisade en ännu högre 
sensitivitet och specificitet för att upptäcka slemhinneläkning.  
Slutsatser 
Koloskopi eller kalprotektinmätning tre månader efter att behandlingen börjat optimerar 
anti-TNF-behandlingen vid Crohns sjukdom. Ett noninvasivt kombinationsindex 
bestående av ett symtomindex och kalprotektin kan bidra till att de begränsade 
koloskopiresurserna koncentreras till de patienter som verkligen behöver genomgå 
koloskopi. 
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